




AU9533736

(12) PATENT ABRIDGMENT (11) Document No. AU-B-33736/95
(19) AUSTRALIAN PATENT OFFICE (10) Acceptance No. 700557

- (54) Title
NOVEL BENZOTHIOPINES HAVING ACTIVITY AS INHIBITORS OF ILEAL BILE ACID TRANSPORT AND TAUROCHOLATE UPTAKE
- International Patent Classification(s)
 (51)⁶ **C07D 337/08 A61K 031/38**
- (21) Application No. : **33736/95** (22) Application Date : **28.08.95**
- (87) PCT Publication Number : **WO96/08484**
- (30) Priority Data
- (31) Number (32) Date (33) Country
305526 13.09.94 US UNITED STATES OF AMERICA
- (43) Publication Date : **29.03.96**
- (44) Publication Date of Accepted Application : **07.01.99**
- (71) Applicant(s)
MONSANTO COMPANY
- (72) Inventor(s)
LEN FANG LEE; RAYMOND EUGENE MILLER; SAMUEL JOSEPH TREMONT
- (74) Attorney or Agent
E F WELLINGTON & CO , 312 St Kilda Road, MELBOURNE VIC 3004
- (56) Prior Art Documents
EP 350846
FR 2661676
WO 93/16055
- (57) Claim

1. A compound of the formula I:



wherein:

- q is an integer of from 1 to 4;
 n is an integer of from 0 to 2;
 R₁ and R₂ are each independently H or C₁₋₁₀ alkyl, or
 R₁ and R₂ taken together form C₃₋₁₀ cycloalkyl, with the proviso that when R₂ is hydrogen, then n cannot be 0;
 R₃ and R₄ are independently H, alkyl, aryl, OR, NRR', or S(O)_nR, or R₃ and R₄ together form =O, =NOH, =S, =NNRR', =NR'', or =CRR', where R, R' and R'' are selected from H, alkyl, alkenylalkyl, alkynylalkyl, aryl, carboxy-alkyl, carboalkoxyalkyl, cycloalkyl, and cyanoalkyl; and

provided that both R_3 and R_4 cannot be OH , NH_2 , or SH ;

R_5 is selected from alkyl, aryl, heterocycle, OR''' , $-NRR'$, and $S(O)_nR$ wherein the alkyl, aryl, and heterocycle are each optionally substituted with alkyl, alkenyl, alkynyl, halogen, OR , NRR' , $S(O)_nR$, NO_2 , haloalkyl, carboxy, carboalkoxy, CN , or $N^+RR'R''Y^-$, wherein R , R' and R'' are each independently as defined above, R''' is alkyl, alkenylalkyl, alkynylalkyl, aryl, carboxyalkyl, carboalkoxyalkyl, cycloalkyl, or cyanoalkyl, and Y is independently an anion, with the proviso that R_5 cannot be NH_2 , or $-NRR'$ when R_1 , R_2 , R_3 , R_4 , and R_6 are all hydrogen, or when R and R' are hydrogen or C_1 - C_6 alkyl;

R_6 is selected from hydrogen or R_4 and R_5 together form $-O-$, or R_5 and R_6 together form a C_3 - C_{10} cycloalkylidene; with the proviso that R_4 and R_6 together can not be $-O-$ when R_3 is OH , NH_2 or SH ;

X is selected from H , alkyl, alkenyl, alkynyl, halogen, OR , NRR' , $NROR'$, $S(O)_nR$, NO_2 , haloalkyl, carboxy, carboalkoxy, CN , and $N^+RR'R''Y^-$, wherein R , R' and R'' are each independently defined as above, and Y is independently an anion;

or a pharmaceutically acceptable salt or solvate thereof.

15. A pharmaceutical composition suitable for the prophylaxis or treatment of hyperlipidemic conditions wherein the condition is atherosclerosis, or a pharmaceutical composition suitable for the prophylaxis or treatment of hyperlipidemic conditions wherein the condition is hypercholesterolemia, which comprise respectively an antiatherosclerotic effective amount of a compound or salt or solvate of formula I/IA according to any one of claims 1, 2 or 4 to 14, or of a compound or salt or solvate of formula IB according to any one of claims 3 to 14, with a pharmaceutically acceptable carrier, or an antihypercholesterolemia effective amount of a compound or salt or solvate of formula I/IA according to any one of claims 1, 2 or 4 to 14, or of a compound or salt or solvate of formula IB according to any one of claims 3 to 14, with a pharmaceutically acceptable carrier.

OPT DATE 29/03/96 APPLN. ID 33736/95
AOJP DATE 23/05/96 PCT NUMBER PCT/US95/10863



AU9533736

(51) International Patent Classification 6 : C07D 337/08, A61K 31/38		A1	(11) International Publication Number: WO 96/08484
			(43) International Publication Date: 21 March 1996 (21.03.96)
(21) International Application Number: PCT/US95/10863		(74) Agent: BOLDING, James, Clifton; Monsanto Company, 800 North Lindbergh Boulevard, St. Louis, MO 63167 (US).	
(22) International Filing Date: 28 August 1995 (28.08.95)		(81) Designated States: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).	
(30) Priority Data: 305,526 13 September 1994 (13.09.94) US		Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(60) Parent Application or Grant (63) Related by Continuation US 305,526 (CIP) Filed on 13 September 1994 (13.09.94)			
(71) Applicant (for all designated States except US): MONSANTO COMPANY [US/US]; 800 North Lindbergh Boulevard, St. Louis, MO 63167 (US).			
(72) Inventors; and (75) Inventors/Applicants (for US only): LEE, Len, Fang [US/US]; 2496 Annapolis Way, St. Charles, MO 63303 (US). MILLER, Raymond, Eugene [US/US]; 9904 Old Lincoln Trail, Fairview Heights, IL 62208 (US). TREMONT, Samuel, Joseph [US/US]; 729 Berquist Drive, St. Louis, MO 63011 (US).			
(54) Title: NOVEL BENZOTHIOPINES HAVING ACTIVITY AS INHIBITORS OF ILEAL BILE ACID TRANSPORT AND TAUROCHOLATE UPTAKE			
(57) Abstract This invention relates to novel benzothiepinines, derivatives and analogs thereof, pharmaceutical compositions containing them and their use in medicine, particularly in the prophylaxis and treatment of hyperlipidemic conditions, such as is associated with atherosclerosis, or hypercholesterolemia, in mammals.			

NOVEL BENZOTHIOPINES HAVING ACTIVITY AS INHIBITORS
OF ILEAL BILE ACID TRANSPORT AND TAUROCHOLATE
UPTAKE

BACKGROUND OF THE INVENTION

5 This invention relates to novel benzothiepinines, derivatives and analogs thereof, pharmaceutical compositions containing them and their use in medicine, particularly in the prophylaxis and treatment of hyperlipidemic conditions, such as is associated with atherosclerosis, or hypercholesterolemia, in mammals.

10 It is well-settled that hyperlipidemic conditions associated with elevated concentrations of total cholesterol and low-density lipoprotein cholesterol are major risk factors for coronary heart disease and particularly atherosclerosis. Interfering with the circulation of bile acids within the lumen of the intestinal tract is found to reduce the levels of serum cholesterol in a causal
15 relationship. Epidemiological data has accumulated which indicates such reduction leads to an improvement in the disease state of atherosclerosis. Stedronsky, in "Interaction of bile acids and cholesterol with nonsystemic agents having hypocholesterolemic properties," Biochimica et Biophysica Acta, 1210 (1994), 255-287 discusses the biochemistry, physiology and known active agents surrounding bile acids and cholesterol.

20 Pathophysiologic alterations are shown to be consistent with interruption of the enterohepatic circulation of bile acids in humans by Heubi, J.E., et al. See "Primary Bile Acid Malabsorption: Defective in Vitro Ileal Active Bile Acid Transport", Gastroenterology, 1992;S3:S04-11.

25 In fact, cholestyramine binds the bile acids in the intestinal tract, thereby interfering with their normal enterohepatic circulation (Reihner, E. et al. in "Regulation of hepatic cholesterol metabolism in humans: stimulatory effects of cholestyramine on HMG-CoA reductase activity and low density lipoprotein receptor expression in gallstone patients", Journal of Lipid Research, Volume 31, 1990, 2219-2226 and Suckling et al. "Cholesterol Lowering and bile acid
30

AUG 1991

- 2 -

excretion in the hamster with cholestyramine treatment", Atherosclerosis, 89(1991) 183-190). This results in an increase in liver bile acid synthesis by the liver using cholesterol as well as an upregulation of the liver LDL receptors which enhances clearance of cholesterol and decreases serum LDL cholesterol levels.

In another approach to the reduction of recirculation of bile acids, the ileal bile acid transport system is a putative pharmaceutical target for the treatment of hypercholesterolemia based on an interruption of the enterohepatic circulation with specific transport inhibitors (Kramer, et al, "Intestinal Bile Acid Absorption" The Journal of Biological Chemistry, Vol. 268, No. 24, Issue of August 25, pp. 18035-18046, 1993).

In a series of patent applications, eg Canadian Patent Application Nos. 2,025,294; 2,078,588; 2,085,782; and 2,085,830; and EP Application Nos. 0 379 161; 0 549 967; 0 559 064; and 0 563 731, Hoechst Aktiengesellschaft discloses polymers of various naturally occurring constituents of the enterohepatic circulation system and their derivatives, including bile acid, which inhibit the physiological bile acid transport with the goal of reducing the LDL cholesterol level sufficiently to be effective as pharmaceuticals and, in particular for use as hypocholesterolemic agents.

In vitro bile acid uptake inhibition is disclosed to show hypolipidemic activity in The Wellcome Foundation Limited disclosure of the world patent application number WO 93/16055 for "Hypolipidemic Benzothiazepine Compounds"

Selected benzothiepienes are disclosed in world patent application number WO93/321146 for numerous uses including fatty acid metabolism and coronary vascular diseases.

Other selected benzothiepienes are known for use as hypolipaemic and hypocholesterolaemic agents, especially for the treatment or prevention of atherosclerosis as disclosed by application Nos. EP 508425, FR 2661676, and WO 92/18462, each of which is limited by an amide bonded to the carbon adjacent the phenyl ring of the fused bicyclo benzothiepine ring.

The above references show continuing efforts to find safe, effective agents for the prophylaxis and treatment of hyperlipidemic


diseases and their usefulness as hypocholesterolemic agents.

Additionally selected benzothiepinines are disclosed for use in various disease states not within the present invention utility. These are EP 568 898A as abstracted by Derwent Abstract No. 93-351589; WO 89/1477/A as abstracted in Derwent Abstract No. 89-370688; U.S. 3,520,891 abstracted in Derwent 50701R-B; US 3,257,370, US 3,389,144; US 3,694,446 abstracted in Derwent Abstr. No. 65560T-B and WO 92/18462.

The present invention furthers such efforts with novel benzothiepinines, pharmaceutical compositions and methods of use therefor

SUMMARY OF THE INVENTION

The present invention provides compounds of the formula (I)



I

wherein:

q is an integer from 1 to 4;

n is an integer of from 0 to 2;

R₁ and R₂ are each independently H or C₁₋₁₀ alkyl, or

R₁ and R₂ taken together form C₂-C₁₀ cycloalkyl, with the proviso that when R₂ is hydrogen, then n cannot be 0;

R₃ and R₄ are independently H, alkyl, aryl, OR, NRR', or S(O)_nR, or R₃ and R₄ together form =C, =NCH, =S, =NRR', =NR'', or =CRR', where R, R' and R'' are selected from H, alkyl, alkynylalkyl, alkynylalkyl, aryl, carboxyalkyl, carboalkoxyalkyl, cycloalkyl, and cyanoalkyl; and provided that both R₃ and R₄ cannot be OH, NH₂, or SH;

R₅ is selected from alkyl, aryl, heterocycle, OR''', -NRR', and S(O)_nR wherein the alkyl, aryl, and heterocycle are each optionally substituted with alkyl, alkynyl, alkynyl, halogen, OR, NRR', S(O)_nR, NO₂, haloalkyl, carboxy, carboalkoxy, CN, or NRR'R''Y', wherein R, R' and R'' are each independently as defined above, R''' is alkyl,


alkenylalkyl, alkynylalkyl, aryl, carboxyalkyl, carboalkoxyalkyl, cycloalkyl, or cyanoalkyl, and Y is independently an anion, with the proviso that R₅ cannot be NH₂, or -NRR' when R₁, R₂, R₃, R₄, and R₆ are all hydrogen, or when R and R' are hydrogen or C₁-C₆ alkyl;

R₆ is selected from hydrogen or R₄ and R₆ together form -O-, or R₅ and R₆ together form a C₃-C₁₀ cycloalkylidene; with the proviso that R₄ and R₆ together can not be -O- when R₃ is CH, NH₂ or SH:

X is selected from H, alkyl, alkenyl, alkynyl, halogen, CR, NRR', NROR', S(O)_nR, NO₂, halcalkyl, carboxy, carbocalkoxy, CN, and N⁺RR'R"Y⁻, wherein R, R' and R" are each independently defined as above, and Y is independently an anion;

or a pharmaceutically acceptable salt or solvate thereof.

The invention also provides compounds of the formula I:



wherein:

q is an integer of from 1 to 4;

n is an integer of from 0 to 2;

R₁ is H or C₁₋₁₀ alkyl; and

R₂ is C₁₋₁₀ alkyl; or

R_1 and R_2 taken together form C_3 - C_{10} cycloalkyl;

R_3 and R_4 are independently H, alkyl, aryl, OR, NRR' , or $S(O)_nR$, or R_3 and R_4 together form $=O$, $=NOH$, $=S$, $=NRR'$, $=P^R$, or $=CRR'$, where R, R' and R" are selected from H, alkyl, alkenylalkyl, alkynylalkyl, aryl, carboxyalkyl, carboalkoxyalkyl, cycloalkyl, and cyanoalkyl; and provided that both R_3 and R_4 cannot be OH, NH_2 , or SH;

R₅ is selected from alkyl, aryl, heterocycle, CR^{'''}, -RR', and S(O)_nR wherein the alkyl, aryl, and heterocycle are each optionally substituted with alkyl, alkenyl, alkynyl, halogen, OR, NRR', S(O)_nR, NO₂, haloalkyl, carboxy, carboalkoxy, CN, or N⁺RR'R''Y⁻, wherein R, R' and R'' are each independently as defined above, R^{'''} is alkyl,

alkenylalkyl-, alkynylalkyl-, aryl-, carboxyalkyl-, carboalkoxyalkyl-,
cycloalkyl-, or cyanoalkyl-, and Y is independently an alkyl-, with the
proviso that R_5 cannot be NH_2 , or NHR when R_1 , R_2 , R_3 , and R_4
are all hydrogen, or when R and R' are both H or C_1 , C_2 , alkyl-

R_5 is selected from hydrogen or R_4 and R_5 together form CH_2 ,
or R_5 and R_6 together form C_1 , C_2 , C_3 , alkyl-, with the
proviso that R_4 and R_5 together cannot form NH when R_1 is H , NH_2
or SH ;

X is selected from H , alkyl-, alkenyl-, alkynyl-, aryl-, heterocycle-, NO_2 ,
 $\text{N(R)OPR}'$, $\text{S(O)}_j\text{R}$, NH_2 , halogen, cyano, carboxy, carboalkoxy, CN , or
 $\text{N(R)R}'\text{R}''\text{Y}$, wherein R, R' and R'' are each independently, as defined
above, and Y is independently an alkyl-

is a pharmaceutically acceptable salt or ester of the compound;
The invention also provides for the use of the compound in

wherein:

i is an integer 1 or 2 or 3;

j is 1 or 2;

R_1 and R_2 are independently H , alkyl-, alkenyl-, alkynyl-, or R_1 and R_2
taken together form C_1 , C_2 , C_3 , C_4 , alkyl-

R_3 and R_4 are independently H , alkyl-, aryl-, OPR' , or
 $\text{S(O)}_j\text{R}$, or R_3 and R_4 together form CH_2 , CHCH_3 , =S , $\text{=C(R)R}'$, $\text{=C(R)R}'$, or
 $\text{=C(R)R}'$, where R, R' and R'' are selected from H , alkyl-, alkenyl-, alkynyl-,
alkynylalkyl-, aryl-, carboxyalkyl-, carboalkoxyalkyl-, cycloalkyl-, and
cyanoalkyl; and provided that both R_3 and R_4 cannot be CH , NH_2 , or
 SH ;

R_5 is selected from alkyl-, aryl-, heterocycle-, OPR' , $\text{N(R)R}'$, and
 $\text{S(O)}_j\text{R}$, wherein the alkyl-, aryl-, and heterocycle are each optionally
substituted with alkyl-, alkenyl-, alkynyl-, halogen, OPR' , $\text{S(O)}_j\text{R}$,
 NO_2 , haloalkyl-, carboxy, carboalkoxy, CN , or $\text{N(R)R}'\text{R}''\text{Y}$, wherein R, R'
and R'' are each independently as defined above, R''' is alkyl-,
alkenylalkyl-, alkynylalkyl-, aryl-, carboxyalkyl-, carboalkoxyalkyl-,

cycloalkyl, or cyanoalkyl, and Y is independently an anion, with the proviso that R_5 cannot be NH_2 , or $-NRR'$ when R_1 , R_2 , R_3 , R_4 , and R_6 are all hydrogen, or when R and R' are hydrogen or C_1 - C_6 alkyl;

- 5 R_6 is selected from hydrogen or R_4 and R_6 together form $-O-$, or R_5 and R_6 together form a C_3 - C_{10} cycloalkylidene; with the proviso that R_4 and R_6 together can not be $-O-$ when R_3 is CH , NH_2 or SH ;


- 10 X is selected from H, alkyl, alkenyl, alkinyl, halogen, OR , NR , $NROR'$, $S(O)_n R$, NO_2 , halocalkyl, carboxy, carbocalkoxy, Cl , and $N^+RR'R''Y^-$, wherein R, R' and R'' are each independently defined as above, and Y is independently an anion;

or a pharmaceutically acceptable salt or solvate thereof.

- 15 Preferred compounds include compounds of formula I wherein R_1 and R_2 cannot both be hydrogen;

Preferred compounds also include compounds of formula I wherein when either R_5 or R_6 is NRR' , then R_3 or R_4 cannot be aryl.

- 20 The more preferred compounds are of the formula I wherein R_1 is butyl, R_2 is ethyl, R_3 is hydrogen, R is hydroxy, R_5 is pival, R_6 is O, n is 2, and X is methoxy as shown below, or enantiomers or mixtures wherein each of R_2 , R_4 and R_5 are in the same stereo relationship to the ring system which may be depicted as follows:



- 25 The invention also provides a pharmaceutical composition for the prophylaxis or treatment of a disease or condition for which a bile acid uptake inhibitor is indicated, such as hyperlipidemic condition, and in particular atherosclerosis, which comprises a compound or salt or solvate of the formula I/IA or of the formula IB in an amount effective for inhibiting the bile acid uptake or the prophylaxis or treatment of the disease or condition benefited thereby and a pharmaceutically acceptable carrier.
- 30

The invention also provides a method of treating a disease or condition in humans for which a bile acid uptake inhibitor is indicated which comprises a compound or salt or solvate of the formula I IA or of the formula IB in unit dosage form.

The present invention also provides a process for the preparation of a compound or salt or solvate of the formula I

The invention also provides the use of a compound or salt or solvate of the formula I IA or of the formula IB, or of said pharmaceutical composition, in the manufacture of a medicament for the treatment or prophylaxis of a condition in humans, in relation to the prophylaxis or treatment of hypercholesterolemia, in conditions wherein the condition is either related or unrelated to the prophylaxis or treatment of hypercholesterolemia, wherein the condition is hypercholesterolemia.

DETAILED DESCRIPTION

"Alkyl" "alkenyl" and "alkynyl" are defined as groups each of from one to six carbon atoms, including the groups, alkenyl and alkynyl, in the present invention and the other groups, methyl, ethyl, propyl, butyl, pentyl or hexyl, and others, including butenyl, pentenyl, or hexenyl, and alkyne, propyne, butyne, pentynyl, or hexynyl respectively and isomers thereof. When any of these groups is referred to as a moiety in a parent molecule, such as alkenylalkyl, these definitions also apply.

"Aryl" is phenyl or naphthyl.

"Heterocycl" is one of the following



or



wherein Z, Z', Z'' or Z''' is C, S, O or N, with the proviso that one of Z, Z', Z'' or Z''' is other than carbon, but is not O or S when attached to another Z atom by a double bond or when attached to another O or S atom. Furthermore, the optional substituents are understood to be attached to Z, Z', Z'' or Z''' only when each is C.

The halogen group meant by "halogen" or meant in haloalkyl is a

- 6 -

fluoro, chloro, bromo or iodo group.

Pharmaceutically acceptable salts are particularly suitable for medical applications because of their greater aqueous solubility relative to the parent. Such salts must clearly have a

5 pharmaceutically acceptable anion or cation. Suitable pharmaceutically acceptable acid addition salts of the compounds of the present invention when possible include those derived from inorganic acids, such as hydrochloric, hydrobromic, phosphoric, metaphosphoric, nitric, sulphonic and sulphuric acids, and organic
10 acids, such as acetic, benzenesulphonic, benzoic, citric, ethanesulphonic, fumaric, gluconic, glycollic, isothionic, lactic, lactobionic, maleic, malic, methansulphonic, succinic, -- toluenesulphonic, tartaric and trifluoroacetic acids. The chloride salt is particularly preferred for medical purposes. Suitable
15 pharmaceutically acceptable base salts include ammonium salts, alkali metal salts, such as sodium and potassium salts, and alkaline earth salts, such as magnesium and calcium salts.

The anions of the definition of Y in the present invention are, of course, also required to be pharmaceutically acceptable and are
20 also selected from the above list.

"Prodrug" is a physiologically functional derivative of a compound of the present invention, for example, an ester, wherein the pharmacologic action of the compound results from conversion by metabolic processes within the body. In other words, such
25 biotransformation upon administration to a mammal, such as a human, is capable of providing (directly or indirectly) the compound or an active metabolite thereof. These prodrugs may or may not be active in their own right.

The compounds of the formula I may have at least two
30 asymmetrical carbon atoms and therefore include rotational isomers. The invention includes all possible stereoisomers, in both pure form and in admixture, including racemic mixtures. Isomers can be prepared using conventional techniques, either by reacting enantiomeric starting materials or by separating isomers of a
35 compound of formula I.

Isomers may include geometric isomers, e.g. when R_1 contains a double bond. All such isomers are contemplated for this invention.

5 In other words, diastereoisomers, enantiomers, racemates and tautomers are contemplated by the present invention.

The compounds of the formula I as referred to in the compositions and methods of use of the present invention are meant to include their salts, solvates and prodrugs as defined herein.

10 The term "a bile acid uptake inhibitor" as used in the present invention refers to inhibition of absorption of bile acids from the intestine of a mammal, such as a human, and includes increasing the fecal excretion of bile acids in a mammal, such as a human, as well as reducing the blood plasma or serum concentrations of cholesterol and cholesterol ester and more specifically reducing LDL
15 and VLDL cholesterol in a mammal, such as a human. Conditions or diseases which benefit from the prophylaxis or treatment by bile acid uptake inhibition are, for example a hyperlipidemic condition, such as atherosclerosis.

20 The starting materials for use in the preparation of the compounds of the invention are known or can be prepared by conventional methods known to a skilled person or in an analogous manner to processes described in the art.

Generally, the compounds of the formula I can be prepared in one of the following procedures.

25 The compounds in this invention can be synthesized by the route shown in scheme 1.

Reaction of aldehyde II with formaldehyde and sodium hydroxide yields the hydroxyaldehyde III which is converted to mesylate IV with methansulfonyl chloride and triethylamine
30 similar to the procedure described in Chem. Ber. 98, 728-734 (1965). Reaction of mesylate IV with thiophenol V, prepared by the procedure described in WO 93/16055, in the presence of triethylamine yields keto-aldehyde VI which can be cyclized with the reagent, prepared from zinc and titanium trichloride in refluxing ethylene
35 glycol dimethyl ether (DME), to give a mixture of 2,3-


dihydrobenzothiepine VII and two racemic stereoisomers of benzothiepin-(5H)-4-one VIII when R₁ and R₂ are nonequivalent.

Oxidation of VII with 3 equivalents of m-chloroperbenzoic acid (MCPBA) gives isomeric sulfone-epoxides IX which upon

5 hydrogenation with palladium on carbon as the catalyst yield a mixture of four racemic stereoisomers of 4-hydroxy-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxides X and two racemic stereoisomers of 2,3,4,5-tetrahydro-benzothiepine-1,1-dioxides XI when R₁ and R₂ are nonequivalent.


10 Optically active compounds of this invention can be prepared by using optically active starting material III or by resolution of compounds X with optical resolution agents well known in the art as described in *J. Org. Chem.*, 39, 3904 (1974), *ibid.*, 42, 2781 (1977), and *ibid.*, 44, 4891 (1979)

Scheme 1



- 10 -

Alternatively, keto-aldehyde VI where R_2 is H can be prepared by reaction of thiophenol V with a 2-substituted acrolein.





- 5 Benzothiepin-(5*H*)-4-one VIII can be oxidized with MCPBA to give the benzothiepin-(5*H*)-4-one-1,1-dioxide XII which can be reduced with sodium borohydride to give four racemic stereoisomers of X. The two stereoisomers of X, Xa and Xb, having the OH group and R_5 on the opposite sides of the benzothiepine ring can be converted to the
- 10 other two isomers of X, Xc and Xd, having the OH group and R_5 on the same side of the benzothiepine ring by reaction in methylene chloride with 40-50% sodium hydroxide in the presence of a phase transfer catalyst (PTC). The transformation can also be carried out
- 15 with potassium t-butoxide in THF.

15

20

25



when $R_1 = \text{Bu}$, $R_2 = \text{Et}$, $R_5 = \text{Ph}$, $X = \text{H}$, $q = 4$

6a = Xa


6b = Xb

6c = Xc

6d = Xd

- 12 -

The compounds of this invention where R_5 is OR, NRR' and $S(O)_nR$ and R_4 is hydroxy can be prepared by reaction of epoxide IX where R_5 is H with thiol, alcohol, and amine in the presence of a base.



$R_5 = OR, NRR', S(O)_nR$


10

Another route to Xc and Xd of this invention is shown in scheme 2. Compound VI is oxidized to compound XIII with two equivalent of m-chloroperbenzoic acid. Hydrogenolysis of compound XIII with palladium on carbon yields compound XIV which can be cyclized with either potassium t-butoxide or sodium hydroxide under phase transfer conditions to a mixture of Xc and Xd. Separation of Xc and Xd can be accomplished with either HPLC or fractional crystallization.

Scheme 2

20

25




30

35

The thiopenols XVIII and V used in this invention can also be prepared according to the scheme 3. Alkylation of phenol XV with an arylmethyl chloride in nonpolar solvent according to the procedure in *J. Chem. Soc.*, 2431-2432 (1958) gives the ortho substituted phenol XVI. The phenol XVI can be converted to the thiophenol XVIII via the thiocarbamate XVII by the procedure described in *J. Org. Chem.*, 31, 3980 (1966). The phenol XVI is first reacted with dimethyl thiocarbamoyl chloride and triethylamine to give thiocarbamate XVII which is thermal rearranged at 200-300 °C and the rearranged product is hydrolyzed with sodium hydroxide to yield the thiophenol XVIII. Similarly, Thiophenol V can also be prepared from 2-acylphenol XIX via the intermediate thiocarbamate XX.

Scheme 3




Scheme 4 shows another route to benzothiepine-1,1-dioxides Xc and Xd starting from the thiophenol XVIII. Compound XVIII can be reacted with mesylate IV to give the sulfide-aldehyde XXI. Oxidation

- 14 -

of XXI with two equivalents of MCPBA yields the sulfone-aldehyde XIV which can be cyclized with potassium t-butoxide to a mixture of Xc and Xd. Cyclization of sulfide-aldehyde with potassium t-butoxide also gives a mixture of benzothiepine XXIIc and XXIIId.

Scheme 4



Examples of amine and hydroxylamine containing compounds of this invention can be prepared as shown in scheme 5 and scheme 6.

35 2-Chloro-4-nitrobenzophenone is reduced with triethylsilane and trifluoromethane sulfonic acid to 2-chloro-4-nitrodiphenylmethane

- 15 -


32. Reaction of 32 with lithium sulfide followed by reacting the resulting sulfide with mesylate IV gives sulfide-aldehyde XXIII. Oxidation of XXIII with 2 equivalents of MCPBA yields sulfone-aldehyde XXIV which can be reduced by hydrogenation to the

5 hydroxylamine XXV. Protecting the hydroxylamine XXV with di-t-butylidicarbonate gives the *N,O*-di-(t-butoxycarbonyl)hydroxylamino derivative XXVI. Cyclization of XXVI with potassium t-butoxide and removal of the t-butoxycarbonyl protecting group gives the a mixture

10 of hydroxylamino derivative XXVIIc and XXVIIId. The primary amine XXXIIIc and XXXIIId derivatives can also be prepared by further hydrogenation of XXIV or XXVIIc and XXVIIId.

- 16 -


Scheme 5



Reduction of the sulfone-aldehyde XXV with hydrogen followed by reductive alkylation of the resulting amino derivative with hydrogen and an aldehyde catalyzed by palladium on carbon in the same reaction vessel yields the substituted amine derivative XXVIII.

- 5 Cyclization of XXVIII with potassium t-butoxide yields a mixture of substituted amino derivatives of this invention XXIXc and XXIXd.


Scheme 6



- 19 -

- Scheme 7 describes one of the methods in introducing a substituent to the aryl ring at the 5-position of benzothiepine. Iodination of 5-phenyl derivative XXX with iodine catalyzed by mercuric triflate gives the iodo derivative XXXI which upon palladium catalyzed carbonylation
- 5 in an alcohol yields the carboxylate XXXII. Hydrolysis of the carboxylate and derivatization of the resulting acid to acid derivatives are well known in the art.

Scheme 7



Abbreviations described in this invention are:

THF---tetrahydrofuran

PTC---phase transfer catalyst

30 Aliquant 336---methyltricaprylammonium chloride

MCPBA---m-chloroperbenzoic acid

Celite--- a brand of diatomaceous earth filtering aid

DMF---dimethylformamide

DME---ethylene glycol dimethyl ether

35 BOC---t-butoxycarbonyl group

The following examples are not meant to be limiting.

EXAMPLES

Preparation 1

2-Ethyl-2-(mesyloxymethyl)hexanal (1)

- 5 To a cold (10 °C) solution of 12.6 g (0.11 mole) of methanesulfonyl chloride and 10.3 g (0.13 mole) of triethylamine was added dropwise 15.8 g of 2-ethyl-2-(hydroxymethyl)hexanal, prepared according to the procedure described in Chem. Ber. 98, 728-734 (1965), while maintaining the reaction temperature below 30 °C. The reaction
10 mixture was stirred at room temperature for 18 h, quenched with dilute HCl and extracted with methylene chloride. The methylene chloride extract was dried over MgSO₄ and concentrated in vacuo to give 24.4 g of brown oil.

Preparation 2

- 15 **2-((2-Benzoylphenylthio)methyl)-2-ethylhexanal (2)**

- A mixture of 31 g (0.144 mol) of 2-mercaptobenzophenone, prepared according to the procedure described in WO 93/16055, 24.4 g (0.1 mole) of 2-ethyl-2-(mesyloxymethyl)-hexanal (1), 14.8 g (0.146 mole) of
20 triethylamine, and 80 mL of 2-methoxyethyl ether was held at reflux for 24 h. The reaction mixture was poured into 3N HCl and extracted with 300 mL of methylene chloride. The methylene chloride layer was washed with 300 mL of 10% NaOH, dried over MgSO₄ and concentrated in vacuo to remove 2-methoxyethyl ether. The residue
25 was purified by HPLC (10% EtOAc-hexane) to give 20.5 g (58%) of 2 as an oil.

Example 1

- 3-Butyl-3-ethyl-5-phenyl-2,3-dihydrobenzothiepine (3), cis-3-Butyl-3-ethyl-5-phenyl-2,3-dihydrobenzothiepin-(5H)4-one (4a) and trans-3-Butyl-3-ethyl-5-phenyl-2,3-dihydro-benzothiepin-(5H)4-one (4b)**
30

- A mixture of 2.6 g (0.04 mole) of zinc dust, 7.2 g (0.047 mole) of TiCl₃ and 80 mL of anhydrous ethylene glycol dimethyl ether (DME) was
35 held at reflux for 2 h. The reaction mixture was cooled to 5 °C. To the

- 22 -

reaction mixture was added dropwise a solution of 3.54 g (0.01 mole) of **2** in 30 mL of DME in 40 min. The reaction mixture was stirred at room temperature for 16 h and then was held at reflux for 2 h and cooled before being poured into brine. The organic was extract into
5 methylene chloride. The methylene chloride extract was dried over MgSO₄ and concentrated in vacuo. The residue was purified by HPLC (hexane) to give 1.7 g (43%) of **3** as an oil in the first fraction. The second fraction was discarded and the third fraction was further purified by HPLC (hexane) to give 0.07 g (2%) of **4a** in the earlier
10 fraction and 0.1 g (3%) of **4b** in the later fraction.

Example 2

cis-3-Butyl-3-ethyl-5-phenyl-2,3-dihydrobenzothiepin-(5*H*)-4-one-1,1-dioxide (**5a**) and *trans*-3-Butyl-3-ethyl-5-phenyl-2,3-dihydro-
15 benzothiepin-(5*H*)-4-one-1,1-dioxide (**5b**)

To a solution of 1.2 g (3.5 mmole) of 50-60% MCPBA in 20 mL of methylene chloride was added 0.59 g (1.75 mmole) of a mixture of **4a** and **4b** in 10 mL of methylene chloride. The reaction mixture was
20 stirred for 20 h. An additional 1.2 g (1.75 mmole) of 50-60% MAPBA was added and the reaction mixture was stirred for an additional 3 h then was triturated with 50 mL of 10% NaOH. The insoluble solid was filtered. The methylene chloride layer of the filtrate was washed with brine, dried over MgSO₄, and concentrated in vacuo. The
25 residual syrup was purified by HPLC (5% EtOAc-hexane) to give 0.2 g (30%) of **5a** as an oil in the first fraction and 0.17 g (26%) of **5b** as an oil in the second fraction.

Example 3

30 (3 α ,4 α ,5 β) 3-Butyl-3-ethyl-4-hydroxy-5-phenyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (**6a**), (3 α ,4 β ,5 α) 3-Butyl-3-ethyl-4-hydroxy-5-phenyl-2,3,4,5-tetrahydro-benzothiepine-1,1-dioxide (**6b**), (3 α ,4 α ,5 α) 3-Butyl-3-ethyl-4-hydroxy-5-phenyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (**6c**), and (3 α ,4 β ,5 β) 3-Butyl-3-

**ethyl-4-hydroxy-5-phenyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide
(6d)**

A. Reduction of 5a and 5b with Sodium Borohydride

5

To a solution of 0.22 g (0.59 mmole) of **5b** in 10 mL of ethanol was added 0.24 g (6.4 mmole) of sodium borohydride. The reaction mixture was stirred at room temperature for 18 h and concentrated in vacuo to remove ethanol. The residue was triturated with water and extracted with methylene chloride. The methylene chloride extract was dried over MgSO₄ and concentrated in vacuo to give 0.2 g of syrup. In a separate experiment, 0.45 g of **5a** was treated with 0.44 g of sodium borohydride in 10 mL of ethanol and was worked up as described above to give 0.5 g of syrup which was identical to the 0.2 g of syrup obtained above. These two materials were combined and purified by HPLC using 10% EtOAc-hexane as eluant. The first fraction was 0.18 g (27%) of **6a** as a syrup. The second fraction was 0.2 g (30%) of **6b** also as a syrup. The column was then eluted with 20% EtOAc-hexane to give 0.077 g (11%) of **6c** in the third fraction as a solid. Recrystallization from hexane gave a solid, mp 179-181 °C. Finally, the column was eluted with 30% EtOAc-hexane to give 0.08 g (12%) of **6d** in the fourth fraction as a solid. Recrystallization from hexane gave a solid, mp 160-161 °C.

25 **B. Conversion of 6a to 6c and 6d with NaOH and PTC**

To a solution of 0.29 g (0.78 mmole) of **6a** in 10 mL CH₂Cl₂, was added 9 g of 40% NaOH. The reaction mixture was stirred for 0.5 h at room temperature and was added one drop of Aliquat-336 (methyltricaprylammonium chloride) phase transfer catalyst (PTC). The mixture was stirred for 0.5 h at room temperature before being treated with 25 mL of ice-crystals then was extracted with CH₂Cl₂ (3x10 ml), dried over MgSO₄ and concentrated in vacuo to recover 0.17 g of a colorless film. The components of this mixture were separated using an HPLC and eluted with EtOAc-hexane to

- 24 -

give 12.8 mg (4%) of 2-(2-benzylphenylsulfonylmethyl)-2-ethylhexenal in the first fraction, 30.9 mg (11%) of **6c** in the second fraction and 90.0 mg (31%) of **6d** in the third fraction.

Oxidation of **6a** to **5b**

5

To a solution of 0.20 g (0.52 mmole) of **6a** in 5 mL of CH₂Cl₂ was added 0.23 g (1.0 mmole) of pyridinium chlorochromate. The reaction mixture was stirred for 2 h then was treated with additional 0.23 g of pyridinium chlorochromate and stirred overnight. The dark reaction mixture was poured into a ceramic filterfrit containing silica gel and was eluted with CH₂Cl₂. The filtrate was concentrated in vacuo to recover 167 mg (87%) of **5b** as a colorless oil.

Example 4

15 **3-Butyl-3-ethyl-5-phenyl-2,3-dihydrobenzothiepine-1,1-dioxide (7)**

To a solution of 5.13 g (15.9 mmole) of **3** in 50 mL of CH₂Cl₂ was added 10 g (31.9 mmole) of 50-60% MCPBA (m-chloroperoxybenzoic acid) portionwise causing a mild reflux and formation of a white solid. The reaction mixture was allowed to stir overnight under N₂ and was triturated with 25 mL of water followed by 50 mL of 10% NaOH solution. The organic was extracted into CH₂Cl₂ (4x20 mL). The CH₂Cl₂ extract was dried over MgSO₄ and evaporated to dryness to recover 4.9 g (87%) of an opaque viscous oil.

25 Example 5

(1 α ,2 β ,8 $\beta\alpha$) 2-Butyl-2-ethyl-8 β -phenyl-1 α ,2,3,8 β -tetrahydro-benzothiepine[4,5-*b*]oxirene-4,4-dioxide (**8a**) (1 α ,2 α ,8 $\beta\alpha$) 2-Butyl-2-ethyl-8 β -phenyl-1 α ,2,3,8 β -tetrahydro-benzothiepine[4,5-*b*]oxirene-4,4-dioxide (**8b**)

30

To 1.3 g (4.03 mmole) of **3** in 25 mL of CHCl₃ was added portionwise 5 g (14.1 mmole) of 50-60 % MCPBA causing a mild exotherm. The reaction mixture was stirred under N₂ overnight and was then held

- 25 -

at reflux for 3 h. The insoluble white slurry was filtered. The filtrate was extracted with 10% potassium carbonate (3x50 mL), once with brine, dried over MgSO₄, and concentrated in vacuo to give 1.37 g of a light yellow oil. Purification by HPLC gave 0.65 g of crystalline product. This product is a mixture of two isomers. Trituration of this crystalline product in hexane recovered 141.7 mg (10%) of a white crystalline product. This isomer was characterized by NMR and mass spectra to be the (1 α ,2 β ,8 β) isomer 8a. The hexane filtrate was concentrated in vacuo to give 206 mg of white film which is a mixture of 30% 8a and 70% 8b by ¹H NMR.

Example 6

cis-3-Butyl-3-ethyl-5-phenyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (9a), trans-3-Butyl-3-ethyl-5-phenyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (9b), and 3-Butyl-3-ethyl-4-hydroxy-5-cyclohexylidene-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (10)

A mixture of 0.15 g (0.4 mmole) of a 3:7 mixture of 8a and 8b was dissolved in 15 ml MeOH in a 3 oz. Fisher/Porter vessel, then was added 0.1 g of 10% Pd/C catalyst. This mixture was hydrogenated at 70 psi H₂ for 5 h and filtered. The filtrate was evaporated to dryness in vacuo to recover 0.117 g of a colorless oil. This material was purified by HPLC eluting with EtOAc-hexane. The first fraction was 4.2 mg (3%) of 9b. The second fraction, 5.0 mg (4%), was a 50/50 mixture of 9a and 9b. The third fraction was 8.8 mg (6%) of 6a. The fourth fraction was 25.5 mg (18%) of 6b. The fifth fraction was 9.6 mg (7%) of a mixture of 6b and a product believed to be 3-butyl-3-ethyl-4,5-dihydroxy-5-phenyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide based on mass spectrum. The sixth fraction was 7.5 mg (5%) of a mixture of 6d and one of the isomers of 10, 10a.

Example 7

In another experiment, a product (3.7 g) from epoxidation of 3 with

- 26 -

excess MCPBA in refluxing CHCl_3 under air was hydrogenated in 100 mL of methanol using 1 g of 10% Pd/C catalyst and 70 psi hydrogen. The product was purified by HPLC to give 0.9 g (25%) of **9b**, 0.45 g (13%) of **9a**, 0.27 g (7%) of **6a**, 0.51 g (14%) of **6b**, 0.02 g (1%) of **6c**, 0.06 g (2%) of one isomer of **10**, **10a** and 0.03 g (1%) of another isomer of **10**, **10b**.

Example 8

2-((2-Benzoylphenylthio)methyl)butyraldehyde (11)

10

To an ice bath cooled solution of 9.76 g (0.116 mole) of 2-ethylacrolein in 40 mL of dry THF was added 24.6 g (0.116 mole) of 2-mercaptobenzophenone in 40 mL of THF followed by 13 g (0.128 mole) of triethylamine. The reaction mixture was stirred at room temperature for 3 days, diluted with ether, and was washed successively with dilute HCl, brine, and 1 M potassium carbonate. The ether layer was dried over MgSO_4 and concentrated in vacuo. The residue was purified by HPLC (10% EtOAc-hexane) to give 22 g (64%) of **11** in the second fraction. An attempt to further purify this material by kugelrohr distillation at 0.5 torr (160-190 °C) gave a fraction (12.2 g) which contained starting material indicating a reversed reaction during distillation. This material was dissolved in ether (100 mL) and was washed with 50 mL of 1 M potassium carbonate three times to give 6.0 g of a syrup which was purified by HPLC (10% EtOAc-hexane) to give 5.6 g of pure **11**.

20

25

Example 9

3-Ethyl-5-phenyl-2,3-dihydrobenzothiepine (12)

30

To a mixture of 2.61 g (0.04 mole) of zinc dust and 60 mL of DME was added 7.5 g (0.048 mole) of TiCl_3 . The reaction mixture was held at reflux for 2 h. A solution of 2.98 g (0.01 mole) of **11** was added dropwise in 1 h. The reaction mixture was held at reflux for 18 h, cooled and poured into water. The organic was extracted into ether. The ether layer was washed with brine and filtered through Celite.

35

- 27 -

The filtrate was dried over MgSO_4 and concentrated. The residual oil (2.5 g) was purified by HPLC to give 2.06 g (77%) of **12** as an oil in the second fraction.

Example 10

- 5 **(1 α ,2 α ,8 $\beta\alpha$) 2-Ethyl-8 β -phenyl-1 α ,2,3,8 β -tetrahydro-benzothiepine-[4,5-*b*]oxirene-4,4-dioxide (13)**

To a solution of 1.5 g (5.64 mmole) of **12** in 25 ml of CHCl_3 was added 6.8 g (19.4 mmole) of 50-60% MCPB portionwise causing
10 an exotherm and formation of a white solid. The mixture was stirred at room temperature overnight diluted with 100 ml methylene chloride and washed successively with 10% K_2CO_3 (4x50 ml), water (2x25 ml) and brine. The organic layer was then dried over MgSO_4 and evaporated to dryness to recover 1.47 g of an off white solid. ^1H
15 NMR indicated that only one isomer is present. This solid was slurried in 200 ml of warm Et_2O and filtered to give 0.82 g (46%) of **13** as a white solid, mp 185-186.5 °C.

Example 11

- 20 **(3 α ,4 β ,5 α)- 3-Ethyl-4-hydroxy-5-phenyl-2,3,4,5-tetrahydro-benzothiepine-1,1-dioxide (14a), (3 α ,4 β ,5 β) 3-Ethyl-4-hydroxy-5-phenyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (14b), and cis-3-Ethyl-5-phenyl-2,3,4,5-tetrahydro-benzothiepine-1,1-dioxide (15)**

- 25 A mixture of 0.5 g (1.6 mole) of **13**, 50 ml of acetic acid and 0.5 g of 10% Pd/C catalyst was hydrogenated with 70 psi hydrogen for 4 h. The crude reaction slurry was filtered and the filtrate was stirred with 150 ml of a saturated NaHCO_3 solution followed by 89 g of NaHCO_3 powder portionwise to neutralize the rest of acetic acid.
30 The mixture was extracted with methylene chloride (4x25 ml), then the organic layer was dried over MgSO_4 and concentrated in vacuo to give 0.44 g (87%) of a voluminous white solid which was purified by HPLC (EtOAc -Hexane) to give 26.8 mg (6%) of **15** in the first fraction,

- 28 -

272 mg (54%) of **14a** as a solid, mp 142-143.5 °C, in the second fraction, and 35 mg (7%) of impure **14b** in the third fraction.

Example 12

5 **2-Ethyl-2-((2-Hydroxymethylphenyl)thiomethyl)hexenal (16)**

A mixture of 5.0 g (0.036 mole) of 2-mercaptobenzyl alcohol, 6.4 g (0.032 mole) of **1**, 3.6 g (0.036 mole) of triethylamine and 25 mL of 2-methoxyethyl ether was held at reflux for 7 h. Additional 1.1 g of
10 mercaptobenzyl alcohol and 0.72 g of triethylamine was added to the reaction mixture and the mixture was held at reflux for additional 16 h. The reaction mixture was cooled and poured into 6N HCl and extracted with methylene chloride. The methylene chloride extract was washed twice with 10% NaOH, dried over MgSO₄ and
15 concentrated in vacuo to give 9.6 g of residue. Purification by HPLC (20% EtOAc-hexane) gave 3.7 g (41%) of **16** as an oil.

Example 13

20 **2-Ethyl-2-((2-formylphenyl)thiomethyl)hexenal (17)**

A mixture of 3.7 g of **16**, 5.6 g (0.026 mole) of pyridinium chlorochromate, 2 g of Celite and 30 mL of methylene chloride was stirred for 18 h and filtered through a bed of silica gel. The silica gel was eluted with methylene chloride. The combined methylene
25 chloride eluant was purified by HPLC (20% ETOAc-hexane) to give 2.4 g (66%) of an oil.

Example 14

30 **3-Butyl-3-ethyl-2,3-dihydrobenzothiepine (18)**

A mixture of 2.6 g (0.04 mole) of zinc dust, 7.2 g (0.047 mole) of TiCl₃, and 50 mL of DME was held at reflux for 2 h and cooled to room temperature. To this mixture was added 2.4 g (8.6 mmole) of **17** in 20 mL of DME in 10 min. The reaction mixture was stirred at room
35 temperature for 2 h and held at reflux for 1 h then was let standing at

- 29 -

room temperature over weekend. The reaction mixture was poured into dilute HCl and was stirred with methylene chloride. The methylene chloride-water mixture was filtered through Celite. The methylene chloride layer was washed with brine, dried over MgSO_4 ,
5 and concentrated in vacuo to give 3.0 g of a residue. Purification by HPLC gave 0.41 g (20%) of 18 as an oil in the early fraction.

Example 15

(1 α ,2 α ,8b α) 2-Butyl-2-ethyl-1a,2,3,8b-tetrahydro-
10 benzothiepine[4,5-b]oxirene-4,4-dioxide (19a) and (1 α ,2 β ,8b α) 2-Butyl-2-ethyl-8b-phenyl-1a,2,3,8b-tetrahydro-benzothiepine[4,5-b]oxirene-4,4-dioxide (19b)

To a solution of 0.4 g of 0.4 g (1.6 mmole) of 18 in 30 mL of methylene chloride was added 2.2 g (3.2 mmole) of 50-60% MCPBA. The reaction
15 mixture was stirred for 2 h and concentrated in vacuo. The residue was dissolved in 30 mL of CHCl_3 and was held at reflux for 18 h under N_2 . The reaction mixture was stirred with 100 mL of 10% NaOH and 5 g of sodium sulfite. The methylene chloride layer was
20 washed with brine, dried over MgSO_4 and concentrated in vacuo. The residue was purified by HPLC (20% EtOAc-hexane) to give a third fraction which was further purified by HPLC (10% EtOAc-hexane) to give 0.12 g of syrup in the first fraction. Recrystallization from hexane gave 0.08 g (17%) of 19a, mp 89.5-105.5 °C. The mother liquor
25 from the first fraction was combined with the second fraction and was further purified by HPLC to give additional 19a in the first fraction and 60 mg of 19b in the second fraction. Crystallization from hexane gave 56 mg of a white solid.

30 Example 16

3-Butyl-3-ethyl-4,5-dihydroxy-5-phenyl-2,3,4,5-tetrahydro-benzothiepine-1,1-dioxide (20)

This product was isolated along with 6b from hydrogenation of a

- 30 -

mixture of 8a and 8b.

Example 17

3-Butyl-3-ethyl-4-hydroxy-5-phenylthio-2,3,4,5-tetrahydro- 5 benzothiepine-1,1-dioxide (21)

A mixture of 25 mg (0.085 mmole) of **19b**, 0.27 g (2.7 mmole) of thiophenol, 0.37 g (2.7 mmole) of potassium carbonate, and 4 mL of DMF was stirred at room temperature under N₂ for 19 h. The
10 reaction mixture was poured into water and extracted with methylene chloride. The methylene chloride layer was washed successively with 10% NaOH and brine, dried over MgSO₄, and concentrated in vacuo to give 0.19 g of semisolid which contain
15 substantial amounts of diphenyl disulfide. This material was purified by HPLC (5% EtOAc-hexane) to remove diphenyl disulfide in the first fraction. The column was then eluted with 20% EtOAc-hexane to give 17 mg of a first fraction, 4 mg of a second fraction and 11 mg of a third fraction which were three different isomers of **21**, i.e. **21a**, **21b**, and **21c**, respectively, by ¹H NMR and mass spectra.

20

Example 18

Alternative Synthesis of 6c and 6d

A. Preparation from 2-((2-Benzoylphenylthio)methyl)-2-ethylhexanal¹ (2)

25 Step 1. 2-((2-Benzoylphenylsulfonyl)methyl)-2-ethylhexanal (44)

To a solution of 9.0 g (0.025 mole) of compound **2** in 100 ml of methylene chloride was added 14.6 g (0.025 mol) of 50-60% MCPBA portionwise. The reaction mixture was stirred at room temperature
30 for 64 h then was stirred with 200 ml of 1 M potassium carbonate and filtered through Celite. The methylene chloride layer was washed twice with 300 ml of 1 M potassium carbonate, once with 10% sodium hydroxide and once with brine. The insoluble solid formed during washing was removed by filtration through Celite. The methylene
35 chloride solution was dried and concentrated in vacuo to give 9.2 g

- 31 -

(95%) of semisolid. A portion (2.6 g) of this solid was purified by HPLC (10% ethyl acetate-hexane) to give 1.9 g of crystals, mp 135-136 °C

Step 2. 2-((2-Benzylphenylsulfonyl)methyl)-2-ethylhexanal (45)

5

A solution of 50 g (0.13 mole) of crude 44 in 250 ml of methylene chloride was divided in two portions and charged to two Fisher-Porter bottles. To each bottle was charged 125 ml of methanol and 5 g of 10% Pd/C. The bottles were pressurized with 70 psi of hydrogen and the reaction mixture was stirred at room temperature for 7 h before being charged with an additional 5 g of 10% Pd/C. The reaction mixture was again hydrogenated with 70 psi of hydrogen for 7 h. This procedure was repeated one more time but only 1 g of Pd/C was charged to the reaction mixture. The combined reaction mixture was filtered and concentrated in vacuo to give 46.8 g of 45 as brown oil.

15

Step 3. (3 α ,4 α ,5 α) 3-Butyl-3-ethyl-4-hydroxy-5-phenyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (6c), and (3 α ,4 β ,5 β) 3-Butyl-3-ethyl-4-hydroxy-5-phenyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (6d)

20

To a solution of 27.3 g (73.4 mmole) of 45 in 300 ml of anhydrous THF cooled to 2 °C with an ice bath was added 9.7 g (73.4 mmole) of 95% potassium t-butoxide. The reaction mixture was stirred for 20 min, quenched with 300 ml of 10% HCl and extracted with methylene chloride. The methylene chloride layer was dried over magnesium sulfate and concentrated in vacuo to give 24.7 g of yellow oil. Purification by HPLC (ethyl acetate-hexane) yielded 9.4 g of recovered 45 in the first fraction, 5.5 g (20%) of 6c in the second fraction and 6.5 g (24%) of 6d in the third fraction.

25

30

B. Preparation from 2-hydroxydiphenylmethane

Step 1. 2-mercaptodiphenylmethane (46)

35

To a 500 ml flask was charged 16 g (0.33 mol) of 60% sodium hydride

- 32 -

oil dispersion. The sodium hydride was washed twice with 50 ml of hexane. To the reaction flask was charged 100 ml of DMF. To this mixture was added a solution of 55.2 g (0.3 mol) of 2-hydroxydiphenylmethane in 200 ml of DMF in 1 h while temperature was maintained below 30 °C by an ice-water bath. After complete addition of the reagent, the mixture was stirred at room temperature for 30 min then cooled with an ice bath. To the reaction mixture was added 49.4 g (0.4 mole) of dimethyl thiocarbamoyl chloride at once. The ice bath was removed and the reaction mixture was stirred at room temperature for 18 h before being poured into 300 ml of water. The organic was extracted into 500 ml of toluene. The toluene layer was washed successively with 10% sodium hydroxide and brine and was concentrated in vacuo to give 78.6 g of a yellow oil which was 95% pure dimethyl *O*-2-benzylphenyl thiocarbamate. This oil was heated at 280-300 °C in a kugelrohr pot under house vacuum for 30 min. The residue was kugelrohr distilled at 1 torr (180-280 °C). The distillate (56.3 g) was crystallized from methanol to give 37.3 g (46%) of the rearranged product dimethyl *S*-2-benzylphenyl thiocarbamate as a yellow solid. A mixture of 57 g (0.21 mole) of this yellow solid, 30 g of potassium hydroxide and 150 ml of methanol was stirred overnight then was concentrated in vacuo. The residue was diluted with 200 ml of water and extracted with ether. The aqueous layer was made acidic with concentrate HCl, The oily suspension was extracted into ether. The ether extract was dried over magnesium sulfate and concentrated in vacuo. The residue was crystallized from hexane to give 37.1 g (88%) of 2-mercaptodiphenylmethane as a yellow solid.

Step 2. 2-((2-Benzylphenylthio)methyl)-2-ethylhexanal (47)

A mixture of 60 g (0.3 mole) of yellow solid from step 1, 70 g (0.3 mole) of compound 1 from preparation 1, 32.4 g (0.32 mole) of triethylamine, 120 ml of 2-methoxyethyl ether was held at reflux for 6 hr and concentrated in vacuo. The residue was triturated with 500 ml of water and 30 ml of concentrate HCl. The organic was extracted into 400 ml of ether. The ether layer was washed successively with brine,

- 33 -

10% sodium hydroxide and brine and was dried over magnesium sulfate and concentrated in vacuo. The residue (98.3 g) was purified by HPLC with 2-5% ethyl acetate-hexane as eluent to give 2-((2-benzylphenylthio)methyl)-2-ethylhexanal **47** as a yellow syrup.

5

Step 3. 2-((2-Benzylphenylsulfonyl)methyl)-2-ethylhexanal (45)

To a solution of 72.8 g (0.21 mole) of yellow syrup from step 2 in 1 liter of methylene chloride cooled to 10 °C was added 132 g of 50-60% MCPBA in 40 min. The reaction mixture was stirred for 2 h. An additional 13 g of 50-60% MCPBA was added to the reaction mixture. The reaction mixture was stirred for 2 h and filtered through Celite. The methylene chloride solution was washed twice with 1 liter of 1 M potassium carbonate then with 1 liter of brine. The methylene chloride layer was dried over magnesium sulfate and concentrated to 76 g of 2-((2-benzylphenylsulfonyl)methyl)-2-ethylhexanal **45** as a syrup.

Step 4. (3 α ,4 α ,5 α) 3-Butyl-3-ethyl-4-hydroxy-5-phenyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (6c), and (3 α ,4 β ,5 β) 3-Butyl-3-ethyl-4-hydroxy-5-phenyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (6d)

Reaction of **45** with potassium t-butoxide according to the procedure in step 3 of procedure A gave pure **6c** and **6d** after HPLC.

Example 19

(3 α ,4 β ,5 β) 3-Butyl-3-ethyl-4-hydroxy-8-methoxy-5-phenyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (25) and (3 α ,4 α ,5 α) 3-Butyl-3-ethyl-4-hydroxy-8-methoxy-5-phenyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (26)

Step 1. Preparation of 2-((2-benzoyl-4-methoxy phenylthio)methyl)-2-ethylhexanal (22)

- 34 -

2-Hydroxy-4-methoxybenzophenone was converted to the dimethyl *O*-2-benzoylphenyl thiocarbamate by methods previously described in example 18. The product can be isolated by recrystallization from ethanol. Using this improved isolation procedure no

5 chromatography was needed. The thermal rearrangement was performed by reacting the thiocarbamate(5 g) in diphenyl ether at 260 °C as previously described. The improved isolation procedure which avoided a chromatography step was described below.

10 The crude pyrolysis product was then heated at 65 °C in 100 ml of methanol and 100 ml of THF in the presence of 3.5 g of KOH for 4 h. After removing THF and methanol by rotary evaporation the solution was extracted with 5 % NaOH and ether. The base layer was acidified and extracted with ether to obtain a 2.9 g of crude thiophenol product.

15 The product was further purified by titrating the desired mercaptan into base with limited KOH. After acidification and extraction with ether pure 2-mercapto-4-methoxybenzophenone (2.3 g) was isolated.

20 2-mercapto-4-methoxybenzophenone can readily be converted to the 2-((2-benzoyl-4-methoxyphenylthio)methyl)-2-ethylhexanal (22) by reaction with 2-ethyl-2-(methoxymethyl)hexanal (1) as previously described.

25 **Step 2. 2-((2-Benzoyl-5-methoxyphenylsulfonyl)methyl)-2-ethylhexanal (23)**

Substrate 22 was readily oxidized to 2-((2-benzoyl-5-methoxyphenylsulfonyl)methyl)-2-ethylhexanal (23) as described in example 18.

30 **Step 3. 2-((2-benzyl-5-methoxyphenylsulfonyl)methyl)-2-ethylhexanal (24)**

Sulfone 23 was then reduced to 2-((2-benzyl-5-methoxyphenylsulfonyl)methyl)-2-ethylhexanal (24) as described in example 18.

35

- 35 -

Step 4. (3 α ,4 β ,5 β) 3-Butyl-3-ethyl-4-hydroxy-8-methoxy-5-phenyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (25) and (3 α ,4 α ,5 α) 3-Butyl-3-ethyl-4-hydroxy-8-methoxy-5-phenyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (26)

5

A 3-neck flask equipped with a powder addition funnel, thermocouple and nitrogen bubbler was charged with 19.8 g (0.05 mole) of sulfone 24 in 100 ml dry THF. The reaction was cooled to -1.6 °C internal temperature by means of ice/salt bath. Slowly add 5.61 g (0.05 mole) of potassium t-butoxide by means of the powder addition funnel. The resulting light yellow solution was maintained at -1.6 °C. After 30 min reaction 400 ml of cold ether was added and this solution was extracted with cold 10 % HCl. The acid layer was extracted with 300 ml of methylene chloride. The organic layers were combined and dried over magnesium sulfate and after filtration stripped to dryness to obtain 19.9 g of product. ¹H nmr and glpc indicated a 96% conversion to a 50/50 mixture of 25 and 26. The only other observable compound was 4% starting sulfone 24.

20 The product was then dissolved in 250 ml of 90/10 hexane/ethyl acetate by warming to 50 °C. The solution was allowed to cool to room temperature and in this way pure 26 can be isolated. The crystallization can be enhanced by addition of a seed crystal of 26. After 2 crystallizations the mother liquor which was now 85.4% 25 and has a dry weight of 8.7 g. This material was dissolved in 100 ml of 90/10 hexane/ethyl acetate and 10 ml of pure ethyl acetate at 40 °C. Pure 25 can be isolated by seeding this solution with a seed crystal of 25 after storing it overnight at 0 °C.

30 **Example 20**

(3 α ,4 α ,5 α) 3-Butyl-3-ethyl-4,8-dihydroxy-5-phenyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (27)

In a 25 ml round bottomed flask, 1 g of 26 (2.5 mmoles) and 10 ml methylene chloride were cooled to -78 °C with stirring. Next 0.7 ml of

- 36 -

boron tribromide(7.5 mmole) was added via syringe. The reaction was allowed to slowly warm to room temperature and stirred for 6 h. The reaction was then diluted with 50 ml methylene chloride and washed with saturated NaCl and then water. The organic layer was dried over magnesium sulfate. The product (0.88g) **27** was characterized by NMR and mass spectra.

Example 21**General Alkylation of phenol **27****

A 25 ml flask was charged with 0.15 g of **27**(0.38 mmole), 5 ml anhydrous DMF, 54 mg of potassium carbonate(0.38 mmole) and 140 mg ethyl iodide (0.9 mmole). The reaction was stirred at room temperature overnight. The reaction was diluted with 50 ml ethyl ether and washed with water (25 ml) then 5% NaOH (20 ml) and then sat. NaCl. After stripping off the solvent the ethoxylated product **28** was obtained in high yield. The product was characterized by NMR and mass spectra.

This same procedure was used to prepare products listed in table 1 from the corresponding iodides or bromides. For higher boiling alkyl iodides and bromides only one equivalent of the alkyl halide was used.




Table 1

Compound No.	R
27	H
26	Me
28	Et
29	hexyl
30	Ac
31	(CH ₂) ₆ -N-phthalimide

Example 22

(3 α ,4 α ,5 α) 3-Butyl-3-ethyl-4-hydroxy-7-hydroxyamino-5-phenyl-
2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (37) and (3 α ,4 β ,5 β) 3-
Butyl-3-ethyl-4-hydroxy-7-hydroxyamino-5-phenyl-2,3,4,5-
5 tetrahydrobenzothiepine-1,1-dioxide (38)

Step 1. Preparation of 2-chloro-5-nitrodiphenylmethane (32)

Procedure adapted from reference :Synthesis -Stuttgart 9 770-772
(1986) Olah G. Et al

10

Under nitrogen, a 3 neck flask was charged with 45 g (0.172 mole) of
2-chloro-5-nitrobenzophenone in 345 ml methylene chloride and the
solution was cooled to ice/water temperature. By means of an
additional funnel, 150 g(0.172 mole) of trifluoromethane sulfonic acid
15 in 345 ml methylene chloride was added slowly. Next 30 g of
triethylsilane (0.172 mole) in 345 ml methylene chloride was added
dropwise to the chilled solution. Both addition steps(
trifluoromethane sulfonic acid and triethylsilane)were repeated.
After the additions were completed the reaction was allowed to slowly
20 warm up to room temperature and stirred for 12 h under nitrogen.
The reaction mixture was then poured into a chilled stirred solution
of 1600 ml of saturated sodium bicarbonate. Gas evolution occurred.
Poured into a 4 liter separatory funnel and separated layers. The
methylene chloride layer was isolated and combined with two 500 ml
25 methylene chloride extractions of the aqueous layer. The methylene
chloride solution was dried over magnesium sulfate and
concentrated in vacuo. The residue was recrystallized from hexane
to give 39 g product . Structure 32 was confirmed by mass spectra
and proton and carbon NMR.

30

Step 2. Preparation of 2-((2-benzyl-4-nitrophenylthio)methyl)-2-ethylhexanal (33)

35

The 2-chloro-5-nitrodiphenylmethane product 32 (40 g, 0.156 mole)
from above was placed in a 2 liter 2 neck flask with water condenser.

Next 150 ml DMSO and 7.18 g (0.156 mole) of lithium sulfide was added and the solution was stirred at 75 °C for 12 h. The reaction was cooled to room temperature and then 51.7 g of mesylate IV was added in 90 ml DMSO. The reaction mixture was heated to 80 °C under nitrogen. After 12 h monitored by TLC and added more mysylate if necessary. Continued the reaction until the reaction was completed. Next the reaction mixture was slowly poured into a 1900 ml of 5% acetic aqueous solution with stirring, extracted with 4 X 700 ml of ether, and dried over MgSO₄. After removal of ether, 82.7 g of product was isolated. The material can be further purified by silica gel chromatography using 95% hexane and 5 % ethyl acetate. If pure mysylate was used in this step there was no need for further purification. The product 33 was characterized by mass spectra and NMR.

Step 3. Oxidation of the nitro product 33 to the sulfone 2-((2-benzyl-4-nitrophenylsulfonyl)methyl)-2-ethylhexanal (34)

The procedure used to oxidize the sulfide 33 to the sulfone 34 has been previously described.

Step 4. Reduction of 34 to 2-((2-benzyl-4-hydroxyaminophenylsulfonyl)methyl)-2-ethylhexanal (35)

A 15 g sample of 34 was dissolved in 230 ml of ethanol and placed in a 500 ml rb flask under nitrogen. Next 1.5 g of 10 wt.% Pd/C was added and hydrogen gas was bubbled through the solution at room temperature until the nitro substrate 34 was consumed. The reaction could be readily monitored by silica gel TLC using 80/20 hexane/EtOAc. Product 35 was isolated by filtering off the Pd/C and then stripping off the EtOH solvent. The product was characterized by NMR and mass spectra.

Step 5. Preparation of the 2-((2-benzyl-4-N,O-di-(t-butoxy-carbonyl)hydroxyaminophenylsulfonyl)methyl)-2-ethylhexanal (36).

- 39 -

A 13.35 g sample of **35** (0.0344 mole) in 40 ml of dry THF was stirred in a 250 ml round bottomed flask. Next added 7.52 g (0.0344 mole) of di-*t*-butyl dicarbonate in 7 ml THF. Heated at 60 °C overnight. Stripped off THF and redissolved in methylene chloride. Extracted with 1 % HCl; and then 5% sodium bicarbonate.

The product was further purified by column chromatography using 90/10 hexane/ethyl acetate and then 70/30 hexane/ethyl acetate. The product **36** was obtained (4.12 g) which appeared to be mainly the di-(*t*-butoxycarbonyl) derivatives by proton NMR.

Step 6. (3 α ,4 α ,5 α) 3-Butyl-3-ethyl-4-hydroxy-7-hydroxyamino-5-phenyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (37) and (3 α ,4 β ,5 β) 3-Butyl-3-ethyl-4-hydroxy-7-hydroxyamino-5-phenyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (38)

A 250ml 3-neck round bottomed flask was charged with 4 g of **36** (6.8 mmoles), and 100 ml of anhydrous THF and cooled to -78 °C under a nitrogen atmosphere. Slowly add 2.29 g potassium *tert*-butoxide (20.4 mmoles) with stirring and maintaining a -78 °C reaction temperature. After 1 h at -78 °C the addition of base was completed and the temperature was brought to -10 °C by means of a ice/salt bath. After 3 h at -10 °C, only trace **36** remained by TLC. Next add 35 ml of deionized water to the reaction mixture at -10 °C and stirred for 5 min. Stripped off most of the THF and added to separatory funnel and extracted with ether until all of the organic was removed from the water phase. The combined ether phases were washed with saturated NaCl and then dried over sodium sulfate. The only products by TLC and NMR were the two BOC protected isomers of **37** and **38**. The isomers were separated by silica gel chromatography using 85% hexane and 15 % ethyl acetate; BOC-**37** (0.71 g) and BOC-**38** (0.78 g).

Next the BOC protecting group was removed by reacting 0.87 g of BOC-38 (1.78 mmoles) with 8.7 ml of 4 M HCl (34.8 mmoles) in dioxane for 30 min. Next added 4.74 g of sodium acetate (34.8 mmoles) to the reaction mixture and 16.5 ml ether and stirred until clear. After transferring to a separatory funnel extracted with ether and water and then dried the ether layer with sodium sulfate. After removing the ether, 0.665 g of 38 was isolated. Isomer 37 could be obtained in a similar procedure.

10 Example 23

(3 α ,4 α ,5 α) 3-Butyl-3-ethyl-7-(n-hexylamino)-4-hydroxy-5-phenyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (40) and (3 α ,4 β ,5 β) 3-Butyl-3-ethyl-7-(n-hexylamino)-4-hydroxy-5-phenyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (41)

15 **Step 1. 2-((2-Benzyl-4-(n-hexylamino)phenylsulfonyl)methyl)-2-ethylhexanal (39)**

In a Fischer porter bottle weighed out 0.5 g of 34 (1.2 mmoles) and dissolved in 3.8 ml of ethanol under nitrogen. Next added 0.1 g of Pd/C and 3.8 ml of hexanal. Seal and pressure to 50 psi of hydrogen gas. Stirred for 48 h. After filtering off the catalyst and removing the solvent by rotary evaporation 39 was isolated by column chromatography (0.16 g) using 90/10 hexane ethyl acetate and gradually increasing the mobile phase to 70/30 hexane/ethyl acetate. The product was characterized by NMR and mass spectra.

30 **Step 2. (3 α ,4 α ,5 α) 3-Butyl-3-ethyl-7-(n-hexylamino)-4-hydroxy-5-phenyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (40) and (3 α ,4 β ,5 β) 3-Butyl-3-ethyl-7-(n-hexylamino)-4-hydroxy-5-phenyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (41)**

A 2-neck, 25 ml round bottomed flask with stir bar was charged with 0.158 g 39 (0.335 mmole) and 5 ml anhydrous THF under nitrogen. Cool to -10 °C by means of a salt/water bath. Slowly add 0.113 g of

potassium tert butoxide (0.335 mmole). After 15 min at -10 °C all of the starting material was consumed by TLC and only the two isomers 40 and 41 were observed. Next added 5 ml of chilled 10% HCl and stirred at -10 °C for 5 min. Transferred to a separatory funnel and extract with ether. Dried over sodium sulfate. Proton NMR of the dried product (0.143 g) indicated only the presence of the two isomers 40 and 41. The two isomers were separated by silica gel chromatography using 90/10 hexane ethyl acetate and gradually increasing the mobile phase to 70/30 hexane/ethyl acetate. 40 (53.2 mg); 41(58.9 mg).

Example 24

Quaternization of amine substrates 40 and 41

Amine products such as 40 and 41 can be readily alkylated to quaternary salts by reaction with alkyl halides. For example 40 in DMF with 5 equivalents of methyl iodide in the presence of 2,6 dimethyl lutidine produces the dimethylhexylamino quaternary salt.

Example 25

(3 α ,4 β ,5 β) 3-Butyl-3-ethyl-4-hydroxy-5-(4-iodophenyl)-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (42)

In a 25 ml round bottomed flask 0.5 g (1.3 mmole) of 6d , 0.67 g of mercuric triflate were dissolved in 20 ml of dry methylene chloride with stirring. Next 0.34 g of Iodine was added and the solution was stirred at room temperature for 30 h. The reaction was then diluted with 50 ml methylene chloride and washed with 10 ml of 1 M sodium thiosulfate; 10 ml of saturated KI ; and dried over sodium sulfate. See Tetrahedron, Vol.50, No. 17, pp 5139-5146 (1994) Bachki, F. Et al. Mass spectrum indicated a mixture of 6d , mono iodide 42 and a diiodide adduct. The mixture was separated by column chromatography and 42 was characterized bt NMR and mass spectra.

- 42 -

Example 26

(3 α ,4 β ,5 β) 3-Butyl-5-(4-carbomethoxyphenyl)-3-ethyl-4-hydroxy-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (43)

5 A 0.1 g sample of 42 (0.212 mmole), 2.5 ml dry methanol, 38 μ l triethylamine (0.275 mmole) , 0.3 ml toluene and 37 mg of palladium chloride (0.21 mmole) was charged to a glass lined mini reactor at 300 psi carbon monoxide. The reaction was heated at 100 °C
10 isolated.

The product was characterized by NMR and mass spectra.

Note the ester functionalized product 43 can be converted to the free
15 acid by hydrolysis.

Example 27

(3 α ,4 α ,5 α) 3-Butyl-3-ethyl-4-hydroxy-7-methoxy-5-phenyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (48), and (3 α ,4 β ,5 β) 3-

Butyl-3-ethyl-4-hydroxy-7-methoxy-5-phenyl-
20 **2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (49)**

Step 1. 2-Mercapto-5-methoxybenzophenone (50)

Reaction of 66.2 g of 4-methoxythiophenol with 360 ml of 2.5 N n-butyllithium, 105 g of tetramethylethylenediamine and 66.7 g of
25 benzonitrile in 600 ml cyclohexane according to the procedure in WO 93/16055 gave 73.2 g of brown oil which was kugelrohr distilled to remove 4-methoxythiophenol and gave 43.86 g of crude 50 in the pot residue.

30 **Step 2. 2-((2-Benzoyl-4-methoxyphenylthio)methyl)-2-ethylhexanal (51)**

Reaction of 10 g (0.04 mole) of crude 50 with 4.8 g (0.02 mole) of mesylate 1 and 3.2 ml (0.23 mole) of triethylamine in 50 ml of diglyme

- 43 -

according to the procedure for the preparation of 2 gave 10.5 g of crude product which was purified by HPLC (5% ethyl acetate-hexane) to give 1.7 g (22%) of 51.

5 **Step 3. 2-((2-Benzoyl-4-methoxyphenylsulfonyl)methyl)-2-ethylhexanal (52)**

10 A solution of 1.2 g (3.1 mmoles) of 51 in 25 ml of methylene chloride was reacted with 2.0 g (6.2 mmoles) of 50-60% MCPBA according to the procedure of step 2 of procedure A in example 18 gave 1.16 g (90%) of 52 as a yellow oil.

15 **Step 4. 2-((2-Benzyl-4-methoxyphenylsulfonyl)methyl)-2-ethylhexanal (53)**

Hydrogenation of 1.1 g of 52 according to the procedure of step 3 of procedure A of example 18 gave 53 as a yellow oil (1.1 g).

20 **Step 5. (3 α ,4 α ,5 α) 3-Butyl-3-ethyl-4-hydroxy-7-methoxy-5-phenyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (48), and (3 α ,4 β ,5 β) 3-Butyl-3-ethyl-4-hydroxy-7-methoxy-5-phenyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (49)**

25 A solution of 1.1 g of 53, 0.36 g of potassium t-butoxide and 25 ml of anhydrous THF was held at reflux for 2 h and worked up as in step 4 of procedure A of example 18 to give 1.07 g of a crude product which was purified by HPLC to give 40 mg (4%) of 48 as crystals, mp 153-154 °C and 90 mg (8%) of 49 as solid, mp 136-140 °C.

30 **Example 28**

5-Phenyl-2,3-dihydrospirobenzothiepine-3,1'-cyclohexane (57)

Step 1. 1-(Hydroxymethyl)-cyclohexanecarboxaldehyde (54)

35 To a cold (0 °C) mixture of 100 g (0.891 mole) of cyclohexanecarboxaldehyde, 76.5 g of 37% of formaldehyde in 225 ml

- 44 -

of methanol was added dropwise 90 ml of 1 N Sodium hydroxide in 1 h. The reaction mixture was stirred at room temperature over 48 then was evaporated to remove methanol. The reaction mixture was diluted with water and extracted with methylene chloride. The organic layer was washed with water, brine, and dried over sodium sulfate and concentrated under vacuum to give 75 g (59.7%) of thick oil. Proton NMR and mass spectra were consistent with the product.

Step 2. 1-(mesyloxymethyl)cyclohexanecarboxaldehyde (55)

To a cold (0 °C) mixture of alcohol 54 (75 g, 0.54 mole) and 65.29 g (0.57 mole) of methanesulfonyl chloride in 80 ml of methylene chloride was added a solution of pyridine (47.96 g, 0.57 mole) in 40 ml of methylene chloride. The reaction mixture was stirred at room temperature for 18 h then quenched with water, acidified with conc. HCl and extracted with methylene chloride. The organic layer was washed with water, brine, and dried over sodium sulfate and concentrated under vacuum to give 91.63 g (77.8%) of thick oil. Proton NMR and mass spectra were consistent with the product.

Step 3. 1-((2-Benzoylphenylthio)methyl)cyclohexanecarboxaldehyde (56)

A mixture of 69 g (0.303 mole) of 2-mercaptobenzophenone, 82 g (0.303 mole) of mesylate 55, 32 g of triethylamine, and 150 ml of diglyme was stirred and held at reflux for 24 h. The mixture was cooled, poured into dil. HCl and extracted with methylene chloride. The organic layer was washed with 10% NaOH, water, brine, and dried over sodium sulfate and concentrated under vacuum to remove excess diglyme. This was purified by silica gel flush column (5% EtOAc: Hexane) and gave 18.6 g (75.9%) of yellow oil. Proton NMR and mass spectra were consistent with the product.

Step 4. 5-Phenyl-2,3-dihydrospirobenzothiepine-3,1'-cyclohexane (57)

- 45 -

To a mixture of 6.19 g of zinc dust and 100 ml of dry DME was added TiCl_3 (16.8 g, 0.108 mole). The reaction mixture was heated to reflux for 2 h. A solution of compound 56 (8.3 g, 0.023 mole) in 50 ml of DME was added dropwise to the reaction mixture in 1 h and the mixture was held at reflux for 18 h. The mixture was cooled, poured into water and extracted with ether. The organic layer was washed with water, brine, and dried over sodium sulfate, filtered through celite and concentrated under vacuum. The residue was purified by HPLC (10% EtOAc: Hexane) to give 4.6 g (64%) of white solid, mp 90-91 °C. Proton and carbon NMR and mass spectra were consistent with the product.

Example 29

8b-Phenyl-1a,2,3,8b-tetrahydrospiro(benzothiepine[4,5-b]oxirene-2,1'-cyclohexane)-4,4-dioxide (58)

To a solution of 57 (4.6 g, 15 mmole) in 50 ml chloroform under nitrogen was added 55% MCPBA (16.5 g, 52.6 mmole) portionwise with spatula. The reaction was held at reflux for 18 h and washed with 10% NaOH(3X), water, brine, and dried over sodium sulfate and concentrated under vacuum to give 5 g of crude product. This was recrystallized from Hexane/EtOAc to give 4.31 g (81%) of yellow solid, mp 154-155 °C. Proton and carbon NMR and mass spectra were consistent with the product.

Example 30

trans-4-Hydroxy-5-phenyl-2,3,4,5-tetrahydro spiro(benzothiepine-3,1'-cyclohexane)-1,1-dioxide (59)

A mixture of 0.5 g (1.4 mmoles) of 58, 20 ml of ethanol, 10 ml of methylene chloride and 0.4 g of 10% Pd/C catalyst was hydrogenated with 70 psi hydrogen for 3 h at room temperature. The crude reaction slurry was filtered through Celite and evaporated to dryness. The residue was purified by HPLC (10% EtOAc-Hexane, 25% EtOAc-Hexane). The first fraction was 300 mg (60%) as a white

- 46 -

solid, mp 99-100 °C. Proton NMR showed this was a trans isomer. The second fraction gave 200 mg of solid which was impure cis isomer.

5 **Example 31**

cis-4-Hydroxy-5-phenyl-2,3,4,5-tetrahydro spiro(benzothiepine-3,1'-cyclohexane)-1,1-dioxide (60)

To a solution of 0.2 g (0.56 mmole) of **59** in 20 ml of CH₂Cl₂, was added
10 8 g of 50% NaOH and one drop of Aliquat-336
(methyltricaprylammonium chloride) phase transfer catalyst. The
reaction mixture was stirred for 10 h at room temperature. Twenty g
of ice was added to the mixture and the mixture was extracted with
CH₂Cl₂ (3x10 ml) washed with water, brine and dried over MgSO₄
15 and concentrated in vacuo to recover 0.15 g of crude product. This
was recrystallized from Hexane/EtOAc to give 125 mg of white
crystal, mp 209-210 °C. Proton and carbon NMR and mass spectra
were consistent with the product.

20 **Example 32**

**(3 α ,4 α ,5 α) 3-Butyl-3-ethyl-4-hydroxy-5-phenyl-2,3,4,5-
tetrahydrobenzothiepine (61), and (3 α ,4 β ,5 β) 3-Butyl-3-ethyl-4-
hydroxy-5-phenyl-2,3,4,5-tetrahydrobenzothiepine (62)**

25 To a solution of 0.5 g (1.47 mmole) of compound **47** in 5 ml of
anhydrous THF was added 0.17 g (1.47 mmole) of 95% potassium t-
butoxide. The reaction mixture was stirred at room temperature for
18 h and quenched with 10 ml of 10% HCl. The organic was extracted
into methylene chloride. The methylene chloride extract was dried
30 over magnesium sulfate and concentrated in vacuo. The residue was
purified by HPLC (2% EtOAc-hexane) to give 47 mg of **61** in the second
fraction and 38 mg of **62** in the third fraction. Proton NMR and mass
spectra were consistent with the assigned structures.

35 **Example 33**

(3 α ,4 α ,5 α) 3-Butyl-3ethyl-4-hydroxy-7-amino-5-phenyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide (63) and (3 α ,4 β ,5 β) 3-Butyl-3-ethyl-4-hydroxy-7-amino-5-phenyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide(64)

An autoclave was charged with 200 mg of 37 in 40 cc ethanol and .02 g 10 % Pd/C. After purging with nitrogen the clave was charged with 100 psi hydrogen and heated to 55 C. The reaction was monitored by TLC and mass spec and allowed to proceed until all of 37 was consumed. After the reaction was complete the catalyst was filtered and the solvent was removed in vacuo and the only observable product was amine 63. This same procedure was used to produce 64 from 38.

The examples herein can be repeated with similar success by substituting the generically or specifically described reactants and/or operating conditions of this invention for those used in the preceding examples.

DOSAGE FORMS

The bile uptake inhibitor compounds of the formula I of this invention can be administered for the prophylaxis and treatment of hyperlipemic diseases or conditions by any means, preferably oral, that produces contact of the compound I with the compound's site of action in the body, for example, preferably in the ileum of a mammal, preferably human.

These agents can be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in a combination of therapeutic agents.

The amount of a compound of formula I which is required to achieve the desired biological effect will, of course, depend on a number of factors such as the specific compound chosen, the use for which it is intended, the mode of administration and the clinical

condition of the recipient.

In general, a daily dose is in the range of from 0.3 to 100 mg (typically from 3 mg to 50 mg) per day per kilogram bodyweight, for example, 3-10 mg/kg/day. This total daily dose is administered to the mammal, preferably human, in single or divided doses, preferably in divided doses 1 to 6 times a day or in sustained release form effective to obtain desired results.

An intravenous dose can, for example, be in the range of from 0.3 mg to 1.0 mg/kg, which is conveniently administered as an infusion of from 10 ng to 100 ng per kilogram per minute. Infusion fluids suitable for this purpose can contain, for example, from 0.1 ng to 10 mg, typically from 1 ng to 10 mg, per milliliter. Unit doses can contain, for example, from 1 mg to 10 g of the compound of the formula I. This ampoules for injection can contain, for example, from 1 mg to 100 mg and orally administrable unit dose formulations, such as tablets or capsules, may contain, for example from 1.0 to 1000 mg, typically from 10 to 500 mg. In the case of pharmaceutically acceptable salts, the weights indicated above refer to the weight of the benzothiepine ion derived from the salt.

For the prophylaxis or treatment of the conditions referred to above, the compounds of formula I can be used as the compound per se, but are preferably presented with an acceptable carrier in the form of a pharmaceutical composition. The carrier must, of course, be acceptable in the sense of being compatible with the other ingredients of the composition and must not be deleterious to the recipient. The carrier can be a solid or a liquid, or both, and is preferably formulated with the compound as a unit-dose composition, for example, a tablet, which can contain from 0.05% to 95% by weight of the active compound. Other pharmacologically active substances can also be present including other compounds of formula I. The pharmaceutical compositions of the invention can be prepared by any of the well known techniques of pharmacy consisting essentially of admixing the components.

Pharmaceutical compositions according to the present invention include those suitable for oral, rectal, topical, buccal (e.g. sublingual) and parenteral (e.g. subcutaneous, intramuscular,

intradermal, or intravenous) administration, although the most suitable route in any given case will depend on the nature and severity of the condition being treated and on the nature of the particular compound of formula I which is being used. Enteric-coated and enteric-coated controlled release formulations are also within the scope of the invention. Suitable enteric coatings include cellulose acetate phthalate, polyvinylacetate phthalate, hydroxypropylmethylcellulose phthalate and anionic polymers of methacrylic acid and methacrylic acid methyl ester.

Pharmaceutical compositions suitable for oral administration can be presented in discrete units, such as capsules, cachets, lozenges, or tablets, each containing a predetermined amount of a compound of formula I; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water or water-in-oil emulsion. As indicated, such compositions can be prepared by any suitable method of pharmacy which includes the step of bringing into association the active compound and the carrier (which can constitute one or more accessory ingredients). In general, the compositions are prepared by uniformly and intimately admixing the active compound with a liquid or finely divided solid carrier, or both, and then, if necessary, shaping the product. For example, a tablet can be prepared by compressing or molding a powder or granules of the compound, optionally with one or more accessory ingredients. Compressed tablets can be prepared by compressing, in a suitable machine, the compound in a free-flowing form, such as a powder or granules optionally mixed with a binder, lubricant, inert diluent and/or surface active/dispersing agent(s). Molded tablets can be made by molding, in a suitable machine, the powdered compound moistened with an inert liquid diluent.

Pharmaceutical compositions suitable for buccal (sub-lingual) administration include lozenges comprising a compound of formula I in a flavored base, usually sucrose and acacia or tragacanth, and pastilles comprising the compound in an inert base such as gelatin and glycerin or sucrose and acacia.

Pharmaceutical compositions suitable for parenteral administration conveniently comprise sterile aqueous preparations

- 50 -

of a compound of formula I. preferably isotonic with the solid of the intended recipient. These preparations are preferably administered intravenously, although administration can also be effected by means of subcutaneous, intramuscular, or intradermal injection.

- 5 Such preparations can conveniently be prepared by admixing the compound with water and rendering the resulting solution sterile and isotonic with the blood. Injectable compositions according to the invention will generally contain from 0.1 to 5% w/w of the compound of the formula I.

- 10 Pharmaceutical compositions suitable for rectal administration are preferably presented as unit-dose suppositories. These can be prepared by admixing a compound of formula I with one or more conventional solid carriers, for example, cocoa butter, and then shaping the resulting mixture.

- 15 Pharmaceutical compositions suitable for topical application to the skin preferably take the form of an ointment, cream, lotion, paste, gel, spray, aerosol, or oil. Carriers which can be used include vaseline, lanoline, polyethylene glycols, alcohols, and combinations of two or more thereof. The active compound is generally present at a concentration of from 0.1 to 15% w/w of the composition, for example, from 0.5 to 2%.

- 20 Transdermal administration is also possible. Pharmaceutical compositions suitable for transdermal administration can be presented as discrete patches adapted to remain in intimate contact with the epidermis of the recipient for a prolonged period of time. Such patches suitably contain the compound of the formula I in an optionally buffered, aqueous solution, dissolved and/or dispersed in an adhesive, or dispersed in a polymer. A suitable concentration of the active compound is about 1% to 35%, preferably about 3% to 15%.
- 25 As one particular possibility, the compound of the formula I can be delivered from the patch by electrotransport or iontophoresis, for example, as described in Pharmaceutical Research, 3(6), 318 (1986).

- 30 The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.
- 35

The dosage regimen to give relief from or ameliorate a disease condition (ie, prophylaxis or treatment) having hyperlipemia as an element of the disease, such as atherosclerosis or protecting against or treating the further high cholesterol plasma or blood levels with the compounds and/or compositions of this invention is selected in accordance with a variety of factors, including the type, age, weight, sex, diet and medical condition of the patient, the severity of the disease, the route of administration, pharmacological considerations such as the activity, efficacy, pharmacokinetics and toxicology profiles of the particular compound employed, whether a drug delivery system is utilized and whether the compound is administered as part of a drug combination. Thus, the dosage regimen actually employed may vary widely and therefore deviate from the preferred dosage regimen set forth above.

Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or setting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

The solid dosage forms for oral administration including capsules, tablets, pills, powders, and granules noted above are the compound of the formula I admixed with at least one inert diluent such as sucrose lactose or starch. Such dosage forms may also comprise, as in normal practice, additional substances other than inert diluents, e.g., lubricating agents such as magnesium stearate. In the case of capsules, tablets, and pills, the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings.

- 52 -

Liquid dosage forms for oral administration may include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water. Such compositions may also comprise adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring, and perfuming agents.

Pharmaceutically acceptable carriers encompass all the foregoing and the like.

BIOLOGICAL ASSAYS

The utility of the compounds of the present invention is shown by the following assays. These assays are performed in vitro and in animal models essentially using a procedure recognized to show the utility of the present invention.

In Vitro Assay of compounds that inhibit IBAT-mediated uptake of [¹⁴C]-Taurocholate (TC) in H14 Cells

Baby hamster kidney cells (BHK) transfected with the cDNA of human IBAT (H14 cells) are seeded at 60,000 cells/well in 96 well Top-Count tissue culture plates for assays run within 24 hours of seeding, 30,000 cells/well for assays run within 48 hours, and 10,000 cells/well for assays run within 72 hours.

On the day of assay, the cell monolayer is gently washed once with 100 μ l assay buffer (Dulbecco's Modified Eagle's medium with 4.5 g/L glucose + 0.2% (w/v) fatty acid free bovine serum albumin-(FAF)BSA). To each well 50 μ l of a two-fold concentrate of test compound in assay buffer is added along with 50 μ l of 6 μ M [¹⁴C]-taurocholate in assay buffer (final concentration of 3 μ M [¹⁴C]-taurocholate). The cell culture plates are incubated 2 hours at 37° C prior to gently washing each well twice with 100 μ l 4° C Dulbecco's phosphate-buffered saline (PBS) containing 0.2% (w/v) (FAF)BSA. The wells are then gently washed once with 100 μ l 4° C PBS without (FAF)BSA. To each 200 μ l of liquid scintillation counting fluid is added, the plates are heat sealed and shaken for 30 minutes at room temperature prior to measuring the amount of radioactivity in each well on a Packard Top-Count instrument.

In Vitro Assay of compounds that inhibit uptake of [¹⁴C]-Alanine

- 53 -

The alanine uptake assay is performed in an identical fashion to the taurocholate assay, with the exception that labeled alanine is substituted for the labeled taurocholate.

- 5 *In Vivo* Assay of compounds that inhibit Rat Ileal uptake of [¹⁴C]-
 Taurocholate into Bile (See "Metabolism of 3 α ,7 β -dihydroxy-7 α -
 methyl-5 β -cholanoic acid and 3 α ,7 β -dihydroxy-7 α -methyl-5 β -
 cholanoic acid in hamsters" in *Biochimica et Biophysica Acta* 833
 (1985) 196-202 by Une et al.)

10

- Male wistar rats (200-300 g) are anesthetized with inactin @100
mg/kg. Bile ducts are cannulated with a 10" length of PE10 tubing.
The small intestine is exposed and laid out on a gauze pad. A
canulae (1/8" luer lock, tapered female adapter) is inserted at 12 cm
15 from the junction of the small intestine and the cecum. A slit is cut
at 4 cm from this same junction (utilizing a 8 cm length of ileum). 20
ml of warm Dulbecco's phosphate buffered saline, pH 6.5 (PBS) is
used to flush out the intestine segment. The distal opening is
cannulated with a 20 cm length of silicone tubing (0.02" I.D. x 0.037"
20 O.D.) The proximal cannulae is hooked up to a peristaltic pump and
the intestine is washed for 20 min with warm PBS at 0.25 ml/min.
Temperature of the gut segment is monitored continuously. At the
start of the experiment, 2.0 ml of control sample ([¹⁴C]-taurocholate
@ 0.05 μ i/ml with 5 mM cold taurocholate) is loaded into the gut
25 segment with a 3 ml syringe and bile sample collection is begun.
Control sample is infused at a rate of 0.25 ml/min for 21 min. Bile
samples fractions are collected every 3 minute for the first 27
minutes of the procedure. After the 21 min of sample infusion, the
ileal loop is washed out with 20 ml of warm PBS (using a 30 ml
30 syringe), and then the loop is washed out for 21 min with warm PBS
at 0.25 ml/min. A second perfusion is initiated as described above but
this with test compound being administered as well (21 min
administration followed by 21 min of wash out) and bile sampled
every 3 min for the first 27 min. If necessary, a third perfusion is
35 performed as above that typically contains the control sample.

Measurement of Hepatic Cholesterol Concentration (HEPATIC CHOL)

Liver tissue was weighed and homogenized in chloroform:methanol (2:1). After homogenization and centrifugation the supernatant was separated and dried under nitrogen. The residue was dissolved in isopropanol and the cholesterol content was measured enzymatically, using a combination of cholesterol oxidase and peroxidase, as described by Allain, C. A., *et al.* (1974) *Clin. Chem.* 20, 470.

Measurement of Hepatic HMG CoA-Reductase Activity (HMG CoA)

Hepatic microsomes were prepared by homogenizing liver samples in a phosphate/sucrose buffer, followed by centrifugal separation. The final pelleted material was resuspended in buffer and an aliquot was assayed for HMG CoA reductase activity by incubating for 60 minutes at 37° C in the presence of ¹⁴C-HMG-CoA (Dupont-NEN). The reaction was stopped by adding 6N HCl followed by centrifugation. An aliquot of the supernatant was separated, by thin-layer chromatography, and the spot corresponding to the enzyme product was scraped off the plate, extracted and radioactivity was determined by scintillation counting. (Reference: Akerlund, J. and Bjorkhem, I. (1990) *J. Lipid Res.* 31, 2159).

Determination of Serum Cholesterol (SER.CHOL, HDL-CHOL, TGI and VLDL + LDL)

Total serum cholesterol (SER.CHOL) was measured enzymatically using a commercial kit from Wako Fine Chemicals (Richmond, VA); Cholesterol C11, Catalog No. 276-64909. HDL cholesterol (HDL-CHOL) was assayed using this same kit after precipitation of VLDL and LDL with Sigma Chemical Co. HDL Cholesterol reagent, Catalog No. 352-3 (dextran sulfate method). Total serum triglycerides (blanked) (TGI) were assayed enzymatically with Sigma Chemical Co. GPO-Trinder, Catalog No. 337-B. VLDL and LDL (VLDL + LDL) cholesterol concentrations were calculated as the difference between total and HDL cholesterol.

Measurement of Hepatic Cholesterol 7- α -Hydroxylase Activity
(7 α -OHase)

Hepatic microsomes were prepared by homogenizing liver samples in a phosphate/sucrose buffer, followed by centrifugal separation. The final pelleted material was resuspended in buffer and an aliquot was assayed for cholesterol 7- α -hydroxylase activity by incubating for 5 minutes at 37° C in the presence of NADPH. Following extraction into petroleum ether, the organic solvent was evaporated and the residue was dissolved in acetonitrile/methanol. The enzymatic product was separated by injecting an aliquot of the extract onto a C₁₈ reversed phase HPLC column and quantitating the eluted material using UV detection at 240nm. (Reference: Horton, J. D., *et al.* (1994) *J. Clin. Invest.* 93, 2084).

15 Measurement of Fecal Bile Acid Concentration (FBA)

Total fecal output from individually housed hamsters was collected for 24 or 48 hours, dried under a stream of nitrogen, pulverized and weighed. Approximately 0.1 gram was weighed out and extracted into an organic solvent (butanol/water). Following separation and drying, the residue was dissolved in methanol and the amount of bile acid present was measured enzymatically using the 3 α -hydroxysteroid steroid dehydrogenase reaction with bile acids to reduce NAD. (Reference: Mashige, F., *et al.* (1981) *Clin. Chem.* 27, 1352).

25 [³H]taurocholate Uptake in Rabbit Brush Border Membrane Vesicles (BBMV)

Rabbit Ileal brush border membranes were prepared from frozen ileal mucosa by the calcium precipitation method describe by Malathi *et al.* (Reference: (1979) *Biochimica Biophysica Acta*, 554, 259). The method for measuring taurocholate was essentially as described by Kramer *et al.* (Reference: (1992) *Biochimica Biophysica Acta*, 1111, 93) except the assay volume was 200 μ l instead of 100 μ l. Briefly, at room temperature a 190 μ l solution containing 2 μ M [³H]-

- 56 -

taurocholate(0.75 μ Ci), 20 mM tris, 100 mM NaCl, 100 mM mannitol pH 7.4 was incubated for 5 sec with 10 μ l of brush border membrane vesicles (60-120 μ g protein). The incubation was initiated by the addition of the BBMV while vortexing and the reaction was stopped by the addition of 5 ml of ice cold buffer (20 mM Hepes-tris, 150 mM KCl) followed immediately by filtration through a nylon filter (0.2 μ m pore) and an additional 5 ml wash with stop buffer.

Acyl-CoA:cholesterol Acyl Transferase (ACAT)

Hamster liver and rat intestinal microsomes were prepared from tissue as described previously (Reference: (1980) *J. Biol. Chem.* 255, 9098) and used as a source of ACAT enzyme. The assay consisted of a 2.0 ml incubation containing 24 μ M Oleoyl-CoA (0.05 μ Ci) in a 50 mM sodium phosphate, 2 mM DTT pH 7.4 buffer containing 0.25 % BSA and 200 μ g of microsomal protein. The assay was initiated by the addition of oleoyl-CoA. The reaction went for 5 min at 37° C and was terminated by the addition of 8.0 ml of chloroform/ methanol (2:1) . To the extraction was added 125 μ g of cholesterol oleate in chloroform methanol to act as a carrier and the organic and aqueous phases of the extraction were separated by centrifugation after thorough vortexing. The chloroform phase was taken to dryness and then spotted on a silica gel 60 TLC plate and developed in hexane/ethyl ether (9:1). The amount of cholesterol ester formed was determined by measuring the amount of radioactivity incorporated into the cholesterol oleate spot on the TLC plate with a Packard instaimager.

Data from each of the noted compounds in the assays described above is as set forth in TABLES 2, 3, 4 and 5 as follows:

30

TABLE 2

COMPOUND	IC50 uM*	In vitro % Inhibition of TC Uptake @ 100 uM #	% Inhibi- tion of Alanine Uptake @ 100 uM #	% of Control Transport of TC in Rat Ileum @ 0.1mM #

	Benzothiazepine-	2		0	45.5 +/- 0.7
	12		25		
	3		0		
5	4a		3		
	5a		34		
	5b	40		0	72.9 ± 5.4 @ 0.5 mM
	4b		9		
	18		6		
10	14b		18		
	14a		13		
	13		23		
	15	60			
	19a		0		
15	19b		15		
	8a		41		
	Mixture of 8a and 8b		69		
20	Mixture of 9a and 9b	6			
	6a	5			
	6b		85		
	9a	5		0 % @ 25 μ M	53.7 +/- 3.9
25	Mixture of 6a and 20	13			
	Mixture of 6d and 10a	0.8		14% @ 25 μ M	
	21a		37		
	21c		52		
30	21b		45		
	6c	2		58.5	68.8 +/- 5.7 at 0.4 mM
	6d	0.6		77.7	16.1 +/- 1.1 @ 0.5 mM 30.2 +/- 0.9 @ 0.15 mM
	17		10		
	7	50		49.3	

- 58 -

5	10a	7		77.6	62.4 $\pm$ 2.5 @ 0.2 mM
	10b	15		68.6	
	25	0.1		4% @ 10 μ M	26.0 $\pm$ 3.3
	26	2		31% @ 25 μ M	87.9 $\pm$ 1.5
	27	5		7% @ 20 μ M	
10	28	8		31% @ 20 μ M	
	29		88 @ 50 μ M		
	30		96 @ 50 μ M		
	31		41 @ 50 μ M		
	37	3		0% @ 5 μ M	
15	38	0.3		11% @ 5 μ M	20.6 $\pm$ 5.7
	40		49 @ 50 μ M		
	41	2		0% @ 20 μ M	
	42	1.5			
	43	1.5		16% @ 25 μ M	
20	48	2		22% @ 20 μ M	
	49	0.15		21% @ 200 μ M	21.2 $\pm$ 2.7
	57		51 @ 50 μ M		
	58		20 @ 50 μ M		
	59	70			
25	60	9		59	
	61	30		175	
	62	10			
	63		90 @ 6 μ M		
	64		100 @ 6 μ M		

* In vitro Taurocholate Cell Uptake

* Unless otherwise noted

- Comparative Example is Example No. 1 in WO 93/16055

- 59 -

TABLE 3					
Compound	TC-uptake	TC-uptake	TC-uptake	ACAT	ACAT
	(H14 cells)	Ileal Loop	(BBMV)	(liver)	(Intestine)
	IC(50)	EC(50)	IC(50)	IC(50)	IC(50)
COMP. EXAMPLE*	1 μ M	74 μ M	3 μ M	20 μ M	20 μ M
6d	0.6 μ M	31 μ M	1.5 μ M	25 μ M	20 μ M
38	0.3 μ M	12 μ M	2 μ M	15 μ M	N.D.
49	0.1 μ M	12 μ M	N.D.	6 μ M	N.D.
25	0.1 μ M	20 μ M	0.8 μ M	8 μ M	8 μ M

Comparative Example is Example No. 1 in WO 93/16055

- 60 -

TABLE 4.
EFFICACY OF COMPOUND NO. 25 IN CHOLESTEROL-FED HAMSTERS

PARAMETER	CONTROL	4% CHOLESTYRAMINE	0.2% CPD. NO. 25
WEIGHT (G)	<i>(mean ± SEM, *p<0.05, A-Student's t, B-Dunnett's)</i>		
day 1	117 (2)	114 (6)	117 (5)
day 14	127 (3)	127 (3)	132 (4)
LIVER WEIGHT (G)	5.4 (0.3)	4.9 (0.4)	5.8 (0.2)
SER.CHOL(mg%)	143 (7)	119 (4)*A,B	126 (2)*A,B
HDL-CHOL(mg%)	89 (4)	76 (3)*A,B	76 (1)*A,B
VLDL + LDL	54 (7)	42 (3)*A	50 (3)
TGI(mg%)	203 (32)	190 (15)	175 (11)
HEPATIC CHOL(mg/g)	2.5 (0.3)	1.9 (0.1)*A,B	1.9 (0.1)*A,B
HMG COA pm/mg/min	15.8 (7.6)	448.8 (21.6)*A,B	312.9 (37.5)*A,B
7a-OHase (pm/mg/min.)	235.3 (25.1)	357.2 (28.3)*A,B	291.0 (6.0)*A
24 HR. FECAL Wt (G)	2.3 (0.1)	2.7 (0.1)*A,B	2.4 (0.04)
FBA (mM/24H/100g)	6.2 (0.8)	12.3 (1.5)*A,B	11.9 (0.5)*A,B


TABLE 5.
EFFICACY OF COMPOUND NO. 25 IN RAT ALZET MINIPUMP MODEL

PARAMETER	CONTROL	20 MPK/DAY CPD. NO. 25
WEIGHT (G)	<i>(mean ± SEM, *p<0.05, A-Student's t, B-Dunnett's)</i>	
day 1	307 (4)	307 (3)
day 8	330 (4)	310 (4)*A,B
LIVER WEIGHT (G)	15.5 (0.6)	14.6 (0.4)
SER.CHOL(mg%)	85 (3)	84 (3)
HEPATIC CHOL(mg/g)	2.1 (0.03)	2.0 (0.03)
HMG COA pm/mg/min	75.1 (6.4)	318.0 (40.7)*A,B
7a-OHase (pm/mg/min.)	281.9 (13.9)	535.2 (35.7)*A,B
24 HR. FECAL Wt (G)	5.8 (0.1)	5.7 (0.4)
FBA (mM/24H/100g)	17.9 (0.9)	39.1 (4.5)*A,B

The foregoing is merely illustrative of the invention and is not intended to limit the invention to the disclosed compounds. Variations and changes which are obvious to one skilled in the art are intended to be within the scope and nature of the invention which are defined in the appended claims.

The claims defining the invention are as follows:

1. A compound of the formula I:



wherein:

5 q is an integer of from 1 to 4;

 n is an integer of from 0 to 2;

 R₁ and R₂ are each independently H or C₁₋₁₀ alkyl, or

 R₁ and R₂ taken together form C₃-C₁₀ cycloalkyl, with the proviso that when R₂ is hydrogen, then n cannot be 0;

 R₃ and R₄ are independently H, alkyl, aryl, OR, NRR', or S(O)_nR, or R₃ and R₄ together form =O, =NOH, =S, =NNRR', =NR'', or =CRR', where R, R' and R'' are selected from H, alkyl, alkenylalkyl, alkynylalkyl, aryl, carboxyalkyl, carboalkoxyalkyl, cycloalkyl, and cyanoalkyl; and provided that both R₃ and R₄ cannot be OH, NH₂, or SH;

 R₅ is selected from alkyl, aryl, heterocycle, O⁺Y⁻, -NRR', and S(O)_nR wherein the alkyl, aryl, and heterocycle are each optionally substituted with alkyl, alkenyl, alkynyl, halogen, OR, NRR', S(O)_nR, NO₂, haloalkyl, carboxy, carboalkoxy, CN, or N⁺RR'R''Y⁻, wherein R, R' and R'' are each independently as defined above, R''' is alkyl, alkenylalkyl, alkynylalkyl, aryl, carboxyalkyl, carboalkoxyalkyl, cycloalkyl, or cyanoalkyl, and Y is independently an anion, with the proviso that R₅ cannot be NH₂, or -NRR' when R₁, R₂, R₃, R₄, and R₆ are all hydrogen, or when R and R' are hydrogen or C₁-C₆ alkyl;

 R₆ is selected from hydrogen or R₄ and R₅ together form -O-, or R₅ and R₆ together form a




C₃-C₁₀ cycloalkylidene; with the proviso that R₄ and R₆ together can not be -O- when R₃ is OH, NH₂ or SH;

X is selected from H, alkyl, alkenyl, alkynyl, halogen, OR, NRR', NROR', S(O)_nR, NO₂, haloalkyl, carboxy, carboalkoxy, CN, and N⁺RR'R"Y⁻, wherein R, R' and R" are each independently defined as above, and Y is independently an anion;

or a pharmaceutically acceptable salt or solvate thereof.

2. A compound of the formula IA:



wherein:

q is an integer of from 1 to 4;

n is an integer of from 0 to 2;

R₁ is H or C₁-10 alkyl; and

R₂ is C₁-10 alkyl; or

R₁ and R₂ taken together form C₃-C₁₀ cycloalkyl;

R₃ and R₄ are independently H, alkyl, aryl, OR, NRR', or S(O)_nR, or R₃ and R₄ together form =O, =NOH, =S, =NNRR', =NR", or =CRR', where R, R' and R" are selected from H, alkyl, alkenylalkyl, alkynylalkyl, aryl, carboxyalkyl, carboalkoxyalkyl, cycloalkyl, and cyanoalkyl; and provided that both R₃ and R₄ cannot be OH, NH₂, or SH;

R₅ is selected from alkyl, aryl, heterocycle, OR''', -NRR', and S(O)_nR wherein the alkyl, aryl, and heterocycle are each optionally substituted with alkyl, alkenyl, alkynyl, halogen, OR, NRR', S(O)_nR, NO₂, haloalkyl, carboxy, carboalkoxy, CN, or N⁺RR'R"Y⁻, wherein R, R' and R" are




each independently as defined above, R''' is alkyl, alkenylalkyl, alkynylalkyl, aryl, carboxyalkyl, carboalkoxyalkyl, cycloalkyl, or cyanoalkyl, and Y is independently an anion, with the proviso that R₅ cannot be NH₂, or -NRR' when R₁, R₃, R₄, and R₆ are all hydrogen, or when R and R' are hydrogen or C₁-C₆ alkyl;

R₆ is selected from hydrogen or R₄ and R₆ together form -O-, or R₅ and R₆ together form a C₃-C₁₀ cycloalkylidene; with the proviso that R₄ and R₆ together can not be -O- when R₃ is OH, NH₂ or SH;

X is selected from H, alkyl, alkenyl, alkynyl, halogen, OR, NRR', NROR', S(O)_nR, NO₂, haloalkyl, carboxy, carboalkoxy, CN, and N⁺RR'R"Y⁻, wherein R, R' and R" are each independently defined as above, and Y is independently an anion;

or a pharmaceutically acceptable salt or solvate thereof.

3. A compound of the formula IB:



IB


wherein:

q is an integer of from 1 to 4;

j is 1 or 2;

R₁ and R₂ are independently H or C₁-₁₀ alkyl, or R₁ and R₂ taken together form C₃-C₁₀ cycloalkyl;

R₃ and R₄ are independently H, alkyl, aryl, OR, NRR', or S(O)_nR, or R₃ and R₄ together form =O, =NOH, =S, =NNRR', =NR", or =CRR', where R, R' and R" are selected from H, alkyl, alkenylalkyl, alkynylalkyl, aryl, carboxyalkyl, carboalkoxyalkyl, cycloalkyl, and cyanoalkyl; and provided that both R₃ and R₄ cannot be OH, NH₂, or SH;



R_5 is selected from alkyl, aryl, heterocycle, OR''' , NRR' , and $S(O)_nR$, wherein the alkyl, aryl, and heterocycle are each optionally substituted with alkyl, alkenyl, alkynyl, halogen, OR , NRR' , $S(O)_nR$, NO_2 , haloalkyl, carboxy, carboalkoxy, CN , or $N^+RR'R''Y^-$, wherein R , R' and R'' are each independently as defined above, R''' is alkyl, alkenylalkyl, alkynylalkyl, aryl, carboxyalkyl, carboalkoxyalkyl, cycloalkyl, or cyanoalkyl, and Y is independently an anion, with the proviso that R_5 cannot be NH_2 , or $-NRR'$ when R_1 , R_2 , R_3 , R_4 , and R_6 are all hydrogen, or when R and R' are hydrogen or C_1-C_6 alkyl;

R_6 is selected from hydrogen or R_4 and R_6 together form $-O-$, or R_5 and R_6 together form a C_3-C_{10} cycloalkylidene; with the proviso that R_4 and R_6 together can not be $-O-$ when R_3 is OH , NH_2 or SH ;

X is selected from H , alkyl, alkenyl, alkynyl, halogen, OR , NRR' , $NROR'$, $S(O)_nR$, NO_2 , haloalkyl, carboxy, carboalkoxy, CN , and $N^+RR'R''Y^-$, wherein R , R' and R'' are each independently defined as above, and Y is independently an anion;

or a pharmaceutically acceptable salt or solvate thereof.

4. A compound or salt or solvate according to any one of claims 1 to 3 wherein when R_5 is NRR' , R_3 or R_4 cannot be aryl.

5. A compound or salt or solvate according to any one of claims 1 to 4 wherein R_4 is OH and R_6 is hydrogen.

6. A compound or salt or solvate according to any one of claims 1 to 5 wherein R_4 and R_5 are in the same plane.

7. A compound or salt or solvate according to any one of claims 3 to 6 wherein both R_1 and R_2 cannot both be hydrogen.



8. A compound or salt or solvate according to any one of claims 1 to 3 wherein R_5 is selected from alkyl, aryl, OR''', and $S(O)_nR$ wherein the alkyl and aryl are each optionally substituted with alkyl, alkenyl, alkynyl, halogen, OR, NRR' , $S(O)_nR$, NO_2 , haloalkyl, carboxy, carboalkoxy, CN, or $N^+RR'R''Y^-$, wherein R, R', R'', R''' and Y are each independently as defined in claim 1.

9. A compound or salt or solvate according to any one of claims 1 to 3 wherein R_3 and R_4 are independently H, alkyl, aryl, OR, or $S(O)_nR$, or R_3 and R_4 together form =O, =NOH, =S, =NNRR', =NR'', or =CRR', where R, R' and R'' are independently as defined in claim 1.

10. A compound of any one of claims 1 to 3 wherein the compound is ($3\alpha, 4\beta, 5\beta$,) 3-butyl-3-ethyl-4-hydroxy-5-phenyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide.

11. A compound of any one of claims 1 to 3 wherein the compound is ($3\alpha, 4\beta, 5\beta$,) 3-butyl-3-ethyl-4-hydroxy-8-methoxy-5-phenyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide.

12. A compound of any one of claims 1 to 3 wherein the compound is ($3\alpha, 4\beta, 5\beta$,) 3-butyl-3-ethyl-4-hydroxy-7-methoxy-5-phenyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide.

13. A compound of any one of claims 1 to 3 wherein the compound is ($3\alpha, 4\beta, 5\beta$,) 3-butyl-3-ethyl-4-hydroxy-7-hydroxy-amino-5-phenyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide.

14. A compound of any one of claims 1 to 3 wherein the compound is ($3\alpha, 4\beta, 5\beta$,) 3-butyl-3-ethyl-4-hydroxy-7-amino-5-phenyl-2,3,4,5-tetrahydrobenzothiepine-1,1-dioxide.



15. A pharmaceutical composition suitable for the prophylaxis or treatment of hyperlipidemic conditions wherein the condition is atherosclerosis, or a pharmaceutical composition suitable for the prophylaxis or treatment of hyperlipidemic conditions wherein the condition is hypercholesterolemia, which comprise respectively an antiatherosclerotic effective amount of a compound or salt or solvate of formula I/IA according to any one of claims 1, 2 or 4 to 14, or of a compound or salt or solvate of formula IB according to any one of claims 3 to 14, with a pharmaceutically acceptable carrier, or an antihypercholesterolemia effective amount of a compound or salt or solvate of formula I/IA according to any one of claims 1, 2 or 4 to 14, or of a compound or salt or solvate of formula IB according to any one of claims 3 to 14, with a pharmaceutically acceptable carrier.

16. A method for the prophylaxis or treatment of hyperlipidemic conditions wherein the condition is atherosclerosis, or for the prophylaxis or treatment of hyperlipidemic conditions wherein the condition is hypercholesterolemia, in a patient in need of said prophylaxis or treatment, which comprises administering to said patient an antihypocholesterolemic effective amount of a compound or salt or solvate of formula I/IA according to any one of claims 1, 2 or 4 to 14, or of a compound or salt or solvate of formula IB according to any one of claims 3 to 14, or of a pharmaceutical composition according to claim 15, respectively, in unit dosage form.

17. The use of a compound or salt or solvate of formula I/IA according to any one of claims 1, 2 or 4 to 14, or of a compound or salt or solvate of formula IB according to any one of claims 3 to 14, or of a pharmaceutical composition of claim 15, respectively, in the manufacture of a medicament



5 formulated so as to be adapted for administration for effective delivery of the active agent(s) to human beings, in relation to the prophylaxis or treatment of hyperlipidemic conditions wherein the condition is atherosclerosis, or in relation to the prophylaxis or treatment of hyperlipidemic conditions wherein the condition is hypercholesterolemia.

DATED this 2nd day of October 1998

MONSANTO COMPANY,
By its Patent Attorneys,
E. F. WELLINGTON & CO.,
By: _____ 6

(Bruce Wellington)

2/10/98 5:53

A/KA/4550

